

HETEROCYCLES, Vol. 81, No. 5, 2010, pp. 1193 - 1229. © The Japan Institute of Heterocyclic Chemistry
Received, 19th January, 2010, Accepted, 1st March, 2010, Published online, 2nd March, 2010
DOI: 10.3987/COM-10-11912

GERANYL DERIVATIVES OF ISOQUINOLINE ALKALOIDS SHOW INCREASED BIOLOGICAL ACTIVITIES

Yumi Nishiyama,^a Kinuko Iwasa,^{*,a} Suguru Okada,^a Sousuke Takeuchi,^a Masataka Moriyasu,^a Miyoko Kamigauchi,^a Junko Koyama,^a Atsuko Takeuchi,^a Harukuni Tokuda,^b Hye-Sook Kim,^c Yusuke Wataya,^c Kazuyoshi Takeda,^d Yi-Nan Liu,^e Pei-Chi Wu,^e Kenneth F. Bastow,^e Toshiyuki Akiyama,^e and Kuo-Hsiung Lee^e

^aKobe Pharmaceutical University, 4-19-1 Motoyamakita, Higashinada-ku, Kobe-shi 658-8558, Japan, ^bDepartment of Biochemistry and Molecular Biology, Kyoto Prefectural University of Medicine, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0841, Japan, ^cFaculty of Pharmaceutical Science, Okayama University, Tsushima, Okayama 700, Japan, ^dYokohama College of Pharmacy, 601 Matanocyo, Hodogayaku, Yokohama-shi 245-0066 Japan, ^eNatural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7360, USA

Abstract – Three types of isoquinoline alkaloids were tested for antimicrobial, cytotoxic, anti-malarial, anti-oxidant, and anti-HIV activities, as well as inhibitory activity against Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in Raji cells. *N*- or *O*-Geranylation contributed to increased potency in four types of activities except anti-HIV and anti-oxidant. Some types of alkaloids may be useful as lead compounds for developing potential chemotherapeutic agents. *N,N*-Geranylated salsolinol was significantly active in three different assays, antimicrobial, cytotoxic, and EBV-EA, and may be a most useful compound.


INTRODUCTION

A number of aromatic prenyltransferases, responsible for prenyl group attachment, have only recently been isolated and characterized.¹⁻⁴ Aromatic prenyltransferases catalyze the transfer of a C₅

(dimethylallyl), C₁₀ (geranyl) or C₁₅ (farnesyl) prenyl group derived from the corresponding isoprenyl diphosphate metabolites onto a variety of electron-rich aromatic acceptors. Prenyl groups appear in a wide variety of bioactive natural products of microbial and plant origin, including amino acids, stilbenes, alkaloids, polyketides and phenylpropanoids such as flavonoids, creating natural product hybrids with altered or enhanced bioactivities. For example, prenylated indole alkaloids containing both aromatic and isoprenoid moieties, are widely distributed in terrestrial and marine organisms.⁵ Prenylation appears in many cases to provide a higher level of bioactivity compared to the nonprenylated precursors and sometimes to cause biological activities distinct from those of the parent compounds.^{6,7} Thus, prenylated compounds represent a new frontier for the development of novel drugs, in particular, anti-microbial, anti-oxidant, anti-inflammatory, anti-viral, and anti-cancer agents. We have previously tested the antimicrobial, antimalarial, cytotoxic, anti-HIV, and anti-oxidant activities and inhibitory effects on EBV-EA induction of isoquinoline alkaloids.^{8,9} Some of the tested isoquinolines showed significant activities in these assays. It was expected that addition of the prenyl group to the isoquinoline alkaloids [simple isoquinolines, 1-benzylisoquinolines, and protoberberines] would increase their potency compared with that of the parent compounds in some assays. In this paper, we describe the synthesis of *N*- and *N,N*-geranyl, and *O*- and *O,O*-geranyl derivatives of isoquinoline alkaloids and compare their activities with those of non-prenylated compounds in five assays: antimicrobial activity, antimalarial activity, cytotoxicity evaluation,¹⁰ inhibitory effects on EBV-EA induction,¹¹ free radical scavenging activity, and anti-HIV activity.¹²


RESULTS AND DISCUSSIONS

Chemistry. Geranylation of ($\pm$)-salsolinol (**1**)⁸ with geranyl bromide and sodium hydride in *N,N*-dimethylformamide has been previously described to give the *N*- and *N,N*-geranyl derivatives (**2**, **3**).¹³ ($\pm$)-*N*-Methylsalsolinol (**4**) and quaternary ($\pm$)-*N,N*-dimethylsalsolinol (**5**) has been prepared from ($\pm$)-carnegine.¹³ Geranylation of **5** by the same methods gave the *O*- and *O,O*-geranyl derivatives (**6-8**) (Scheme 1). Geranylation of ($\pm$)-tetrahydropapaveroline (**9**)⁹ gave the *N*- and *N,N*-geranyl derivatives (**10** and **11**), and ($\pm$)-*N*-methylpapaveroline (**12**) produced the *O,O*-geranyl derivative (**13**) (Scheme 2). Geranylation of ($\pm$)-2,3,9,10-tetrademethyltetrahydropalmatine (**14**)⁹ afforded the *N*-geranyl derivatives (**15** and **16**) and ($\pm$)-2,3,10,11-tetrademethylpseudotetrahydropalmatine (**17**)⁹ gave the *N*-geranyl derivative (**18**) (Scheme 3). Each geranylated compound was purified by preparative HPLC of the reaction mixtures using NH₄OAc (0.05% TFA)-MeOH (0.05% TFA).



Scheme 1. *N*-geranylation of simple isoquinolines


The HPLC of the reaction mixture in geranylation of salsolinol (**1**) is shown in Figure 1 (I). The peaks a_1 and b_1 were determined to be (±)-*N*-geranylsalsolinol (**2**) and (±)-*N,N*-digeranylsalsolinol (**3**), respectively (Scheme 1). Their structures, including the stereostructure, have been previously described:¹³ orientation of the C (1)-methyl group is quasi-axial in **2** and **3** and that of the *N*-geranyl group is quasi-equatorial in **2**.



Scheme 2. *N*-geranylation of 1-benzylisoquinolines

These stereostructures were identical with the optimized geometry of **2** and **3** calculated. The optimized geometry and molecular orbital of **2** and **3** were calculated by the DFT (Density Function Theory) method using the Materials Studio DMol3 package of Accelrys Inc.^{14,15} (Figure 1) and they may be necessary to clarify the biological activities' mechanisms.

HPLC of the reaction mixture in geranylation of $(\pm)\text{-}N,N$ -dimethylsalsolinol (**5**) is shown in Figure 1. Compounds **6-8**, corresponding to the peaks a_2 , b_2 , and c_2 , respectively, (Figure 1, II) were separated and purified by preparative HPLC. The molecular formula of compound **6** was determined to be $\text{C}_{22}\text{H}_{34}\text{NO}_2$ by analysis of its HRSIMS ($[\text{M}]^+$, m/z 344.2606), which indicates the presence of one geranyl group.



Scheme 3. *N*-geranylation of tetrahydroprotoberberines

The ^1H NMR spectrum displays two aromatic proton singlets at δ 6.68 and 6.74, a methine proton at δ 4.57 (q, $J = 6.5$ Hz), two methylene groups [δ 3.77 (1H), 3.55 (1H), and 3.08 (2H)], two *N*-methyl proton signals [δ 3.17 (3H) and 3.14 (3H)], and a methyl proton signal [δ 1.69 (3H, d, $J = 6.5$ Hz)], characteristic of the isoquinoline moiety, and three methyl proton signals at δ 1.75 (3H, s), 1.65 (3H, s), and 1.59 (3H, s), two olefinic protons at δ 5.48 (1H, t, $J = 6.5$ Hz) and 5.09 (1H, t, $J = 6.5$ Hz), and three methylene groups [δ 4.62 (2H, d, $J = 6.5$), δ 2.12 (2H, m), and δ 2.09 (2H, m)], assignable to the geranyl group. The olefinic protons at δ 5.48 and 5.09 show COSY coupling to the methylene protons at δ 4.62 and 2.12, respectively, which led to the assignment of H-2' (δ 5.48) and H-6' (δ 5.09), respectively. The methylene protons at δ 4.62 and 2.12 were assigned to H₂-1' and H₂-5', respectively.






Figure 1. Analytical scale HPLC chromatograms of geranylated products of I: salsolinol (1), II: *N, N*-dimethylsalsolinol (5), and III: tetrahydropapaveroline (9)

Column: Cosmosil 5C18-ARII (6.0 x 150 mm); Eluent: A:0.1M NH₄OAc (0.05% TFA), B:MeOH (0.05% TFA), I and II [A/B: 80/20 (initial) 0/100 (30 min)]; III [A/B: 75/25 (initial) 50/50 (10 min) 0/100 (30 min)]; Flow rate: 1 mL/min; Detector: UV(280 nm)



Optimized geometry of *N*-geranylsalsolinol (2)
E=-986.0139433 Ha (BLYP/DNP)



Optimized geometry of *N,N*-digeranylsalsolinol (3)
E=-1376.8807811 Ha (BLYP/DNP)

The NOE correlations between an aromatic proton at δ 6.74 and a proton at δ 4.57 (H-1) indicated that this aromatic proton was assigned as H-8. The aromatic proton at δ 6.68, which was correlated with the methylene protons at δ 3.08 (H₂-4) was assigned as H-5. NOE correlations were also observed between the aromatic proton at δ 6.74 (H-8) and methylene protons at δ 4.62 (H-1'), indicating that a geranyl group was attached to oxygen at C-7. Based on the above evidence, compound **6** was indicated to be 7-*O*-geranyl-*N, N*-dimethylsalsolinol (Scheme 1). Moreover, the ¹³C NMR spectrum of **6** supports this assignment, with signals corresponding to 22 carbons, including two protonated olefinic carbons (δ 124.90; 120.94), two protonated aromatic carbons (δ 116.01; 113.25), six quaternary carbons (δ 148.79; 147.83; 142.30; 132.63; 124.39; 122.17), five methylene carbons (δ 67.06; 56.86; 40.61; 27.41; 24.30), a methine carbon (δ 69.51), two *N*-methyl carbons (δ 51.50; 50.11) and four methyl carbons (δ 25.84; 18.63; 17.72; 16.69). The carbon signal at δ 147.83 (C-7) displays HMBC correlations with the proton signal at δ 4.62 (H-1'), confirming 7-*O*-geranylation, which was already suggested by the NOE correlation between H-8 and H-1'. On the basis of these data, the structure of **6**

was established to be ($\pm$)-7-*O*-geranyl-*N,N*-dimethylsalsolinol.

The molecular formula of compound **7** was determined to be $C_{22}H_{34}NO_2$ by analysis of its HRSIMS ($[M]^+$, m/z 344.2603), which indicated the presence of one geranyl group. The 1H NMR spectrum is almost the same with that of **6**. The NOE correlations between the aromatic proton at δ 6.66 and δ 4.55 (H-1) and the aromatic proton at δ 6.79 and the methylene protons at δ 3.12 (H₂-4) indicate that the aromatic protons at δ 6.66 and 6.79 were assigned to H-8 and H-5, respectively. NOE correlations were also observed between the aromatic proton at δ 6.79 (H-5) and methylene protons at δ 4.63 (H-1'), indicating that a geranyl group is attached to oxygen at C-6. Based on the above evidence, compound **7** was found to be 6-*O*-geranyl-*N,N*-dimethylsalsolinol (Scheme 1). Moreover, the ^{13}C NMR spectrum of **7** supports this structure, with signals corresponding to 22 carbons. The carbon signal at δ 148.62 (C-6) display HMBC correlations with the proton signal at δ 4.63 (H-1'), confirming 6-*O*-geranylation, which was suggested by the NOE correlation between H-5 and H-1'. On the basis of these data, the structure of **7** was confirmed to be ($\pm$)-6-*O*-geranyl-*N,N*-dimethylsalsolinol.

The molecular formula of compound **8** was determined to be $C_{32}H_{50}NO_2$ by analysis of its HRSIMS ($[M]^+$, m/z 480.3858), which indicated the presence of two geranyl groups. The 1H NMR spectrum displays two aromatic protons as singlets at δ 6.83 and 6.79, a methine proton at δ 4.54 (q, J = 6.5 Hz), two methylene groups [δ 3.79 (1H), 3.57 (1H), and 3.14 (2H)], two *N*-methyl groups [δ 3.17 (3H) and 3.15 (3H)], and a methyl proton signal [δ 1.69 (3H, d, J = 6.5 Hz)], characteristic of an isoquinoline moiety, and six methyl proton signals at δ 1.66 (6H, s), 1.60 (6H, s), 1.736 (3H, s), and 1.742 (3H, s), four olefinic protons at δ 5.48 (2H) and 5.10 (2H), and six methylene groups [δ 4.58 (2H), 4.59 (2H), 2.12 (4H, m), and δ 2.07 (4H)], assignable to two geranyl groups. The aromatic proton at δ 6.83 shows NOE correlations with both methylene protons at δ 3.14 (H-4) and 4.58 (or 4.59, H-1'). This aromatic proton was assigned H-5. Therefore, the geranyl group is attached to the oxygen at C-6. The aromatic proton at δ 6.79 displays NOE correlations with protons at δ 4.54 (H-1), 4.59 (or 4.58, H-1''), and 1.69 (1-Me) indicating that this aromatic proton was H-8. This indicated that the other geranyl group is attached to the oxygen at C-7. From these data, the structure of **8** was deduced to be 6, 7-*O*-digeranyl-*N,N*-dimethylsalsolinol (Scheme 1). The ^{13}C NMR spectrum of **8** supports this structure.

Assignments of 1H and ^{13}C signals of **6-8** were made by 1D and 2D (1H - 1H COSY, NOESY, HSQC, and HMBC) spectroscopic data. The geometry of the disubstituted olefinic bonds (between 2' and 3' or 2'' and 3'') was determined to be *E* on the basis of the NOE correlation between H-2' and H-4' or H-2'' and H-4'', respectively. The NOE correlations between H-1 and both quasi-equatorial and quasi-axial *N*-methyl groups indicate the quasi-equatorial orientation of H-1, that is, quasi-axial orientation of the methyl group at C-1. These stereostructures were identical with the optimized geometry of **6-8**

calculated.

HPLC of the reaction mixture in geranylation (Scheme 2) of ($\pm$)-tetrahydropapaveroline (**9**) is shown in Figure 1 (III). The compounds corresponding to the peaks a_3 and b_3 (Figure 1, III) (**10** and **11**) were purified by prep. HPLC of the reaction mixture. The molecular formula of compound **10** (peak a_3) was determined to be $C_{26}H_{34}NO_4$ by analysis of its HRSIMS ($[M + H]^+$, m/z 424.2494), which indicates the presence of one geranyl group. The 1H NMR spectrum displays two aromatic proton singlets at δ 6.65 and 6.18, a methine proton at δ 4.42 (1H, t, $J = 6.5$ Hz), two methylene groups [δ 3.68 (1H), 3.38 (1H), and 2.97 (2H)] arisen from the isoquinoline moiety, three aromatic protons at δ 6.75 (1H, d, $J = 8.5$ Hz), 6.50 (1H, brd, $J = 8.5$ Hz), and 6.58 (1H, brs), methylene protons [δ 3.04 (1H) and 3.14 (1H)] characteristic of a benzyl group, and three methyl proton signals at δ 1.70 (3H, s), 1.64 (3H, s), and 1.57 (3H, s), two olefinic protons at δ 5.26 (1H, m) and 5.12 (1H, m), and three methylene groups [δ 3.83 (1H), δ 3.71 (1H), and δ 2.18 (4H)], assignable to a geranyl group. The NOE correlations between the methylene protons (H-1'') of the geranyl group and both the methine proton (H-1) of the isoquinoline structure and the methylene protons (H-9) of the benzyl group indicate that the geranyl group was attached to nitrogen. Based on the these evidences, compound **10** was established to be ($\pm$)-*N*-geranyltetrahydropapaveroline (Scheme 2). The ^{13}C NMR spectrum of **10** supports this structure, with signals corresponding to 24 carbons (two carbons overlap), including two protonated olefinic carbons (δ 124.56; 114.15), five protonated aromatic carbons (δ 121.87; 117.67; 116.76; 116.12; 115.75), nine quaternary carbons (δ 149.65; 147.30; 146.92; 146.04; 145.65; 133.29; 121.93; 121.87x2), six methylene carbons (δ 51.86; 44.80; 40.74x2; 27.14; 22.90), a methine carbon (δ 63.01), and three methyl carbons (δ 25.94; 17.84; 16.80). Assignments of 1H and ^{13}C signals of **10** were made by 1D and 2D (1H - 1H COSY, NOESY, HSQC, and HMBC) spectroscopic data. The geometry of the disubstituted olefinic bond (between 2'' and 3'') was determined to be *E* on the basis of the NOE correlation between H-2'' and H-4''. The geranyl group may be a quasi-equatorial orientation, because a methylene proton (H-1'') of the geranyl group displayed NOE correlations with both the methine proton (H-1) of the isoquinoline structure and the methylene protons (H-9) of the benzyl group. Therefore, the benzyl group is considered to be quasi-axial orientation. The upfield shift (+ 3.6 ppm) at C-3 in **10** compared with *N*-methylsalsolinol (**4**) is interpreted as being due to larger steric compression by the quasi-axial benzyl group at C-1 in **10** than that by the quasi-axial methyl group at C-1 in **4**.

The molecular formula of compound **11** (peak b_3) was determined to be $C_{36}H_{50}NO_4$ by analysis of its HRSIMS ($[M]^+$, m/z 560.3746), which indicates the presence of two geranyl groups. The 1H NMR and ^{13}C NMR spectra of **11** display the signals due to the 1-benzyltetrahydroisoquinoline structure and two sets of signals due to two geranyl groups. The protons at δ 3.78 (H-1'') and 4.13 (H-1''') show HMBC

correlations with carbons at δ 58.30 (C-1''') and 55.79 (C-1''), respectively. Furthermore, HMBC correlations were observed from protons at δ 3.96 (H-1'') and δ 4.13 (H-1''') to the carbon at δ 52.01 (C-3). The proton at δ 4.20 (H-1''') also shows a correlation with the carbon at δ 70.72 (C-1). It was concluded that both geranyl groups are attached to nitrogen on the basis of these HMBC correlations, as well as by NOE correlations between H-1 (δ 4.42) and H-1'' (δ 3.96), H-3 (δ 3.53) and H-1''' (δ 4.20), and H-3 (δ 3.68) and H-1''' (δ 4.13 and δ 4.20), respectively. Assignments of ^1H and ^{13}C signals of **11** were made by 1D and 2D (^1H - ^1H COSY, NOESY, HSQC, and HMBC) spectroscopic data. Based on these evidences, compound **11** was determined to be ($\pm$)-*N,N*-digeranyltetrahydropapaveroline (Scheme 2). The geometries of the disubstituted olefinic bonds (between 2'' and 3'' and between 2''' and 3''') were determined to be *E* on the basis of the NOE correlations between H-2'' and H-4'', and H-2''' and H-4''', respectively. NOE correlations were observed between the proton at δ 4.20 (H-1''') and H₂-3 at δ 3.68 and 3.53 (quasi-axial and quasi-equatorial protons), indicating that C-1''' of the geranyl group is a quasi-equatorial orientation. The quasi-equatorial orientation of the proton at C-1 was suggested by the NOE correlations between the methine proton at δ 4.42 (H-1) and the proton (δ 3.96) of C-1'' of the quasi-axial geranyl group. Therefore, the orientation of the benzyl group is quasi-axial. This was suggested from the fact that the upfield shift (+ 4.1 ppm) at C-3 in **11** compared with *N,N*-dimethylsalsolinol (**5**) arises from larger steric compression by the quasi-axial benzyl group at C-1 in **11** than that by the quasi-axial methyl group at C-1 in **5**.

HPLC of the reaction mixture in geranylation (Scheme 2) of *N*-methylpapaveroline (**12**) is shown in Figure 2 (I). Some compounds (peaks a₄, b₄, and d₄) in the reaction mixture changed during prep.




Figure 2. Analytical scale HPLC chromatograms of products obtained by geranylation of I: *N*-methylpapaveroline (**12**),

II: 2, 3, 9, 10-tetrademethyltetrahydropalmatine (**14**), and III: 2, 3, 10, 11-tetrademethylpseudotetrahydropalmatine (**17**)

Column: Cosmosil 5C₁₈-ARII (6.0 x 150 mm); Eluent: A: 0.1M NH₄OAc (0.05% TFA), B: MeOH (0.05% TFA), I [A/B: 75/25

(initial) 50/50 (10 min) 0/100 (30 min)], II and III [A/B: 80/20 (initial) 0/100 (20 min)]; Flow rate: 1 mL/min; Detector: UV(280 nm)

HPLC and were not purified. Only peak **c**₄ was purified by prep. HPLC. The molecular formula of compound **13** (peak **c**₄) was determined to be C₃₇H₄₈NO₄ by analysis of its HRSIMS ([M]⁺, *m/z* 570.3592), which indicates the presence of two geranyl groups. The ¹H NMR spectrum displays two aromatic protons as doublets at δ 8.32 and 8.08 (*J* = 7.0 Hz), two aromatic protons as singlets at δ 7.70 and 7.60 originating in the isoquinoline moiety, three aromatic protons at δ 6.71 (1H, d, *J* = 8.5 Hz), 6.36 (1H, dd, *J* = 8.5, 1.5 Hz), and 6.49 (1H, d, 1.5 Hz), a methylene proton at δ 4.83 (2H) characteristic of a benzyl group, six methyl proton signals at δ 1.83 (3H, s), 1.70 (3H, s), 1.61 (3H, s), 1.59 (3H, s), 1.58 (3H, s), and 1.55 (3H, s), four olefinic protons at δ 5.58 (1H), 5.39 (1H), 5.09 (1H), and 5.02 (1H), and six methylene groups [δ 4.90 (2H), 4.80 (2H), 2.15 (2H), 2.13 (2H), 2.05 (2H), and 1.98 (2H)], assignable to two geranyl groups. The aromatic proton at δ 7.60 shows NOE correlations with both protons at δ 8.08 (H-4) and 4.90 (H-1''). Thus, the proton at δ 7.60 was assigned to H-5. Therefore, the geranyl group is attached to the oxygen at C-6. The aromatic proton at δ 7.70 displays NOE correlations with protons at δ 4.80 (H-1'''), indicating that this proton is H-8. This indicates that the other geranyl group is attached to the oxygen at C-7. Based on these evidences, compound **13** was identified as *O,O*-digeranylpapaveroline (Scheme 2). Moreover, the ¹³C NMR spectrum of **13** shows four protonated olefinic carbons (δ 124.91; 124.84; 119.65; 119.32), seven protonated aromatic carbons (δ 136.61; 123.58; 120.39; 117.14; 116.13; 108.15; 108.08), 12 quaternary carbons (δ 158.86; 156.93; 154.18; 147.50; 146.17; 144.48; 143.93; 137.50; 132.81; 132.63; 126.47; 125.62), seven methylene carbons (δ 67.71; 67.33; 40.63; 40.46; 34.96; 27.30; 27.29), one *N*-methyl carbon (δ 46.28), and six methyl carbons (δ 25.91; 25.87; 17.82; 17.81; 16.88; 16.84). The carbon signal at δ 158.86 (C-6) displayed HMBC correlations with the proton signal at δ 4.90 (H-1''), confirming 6-*O*-geranylation, which was also suggested by the NOE correlation between H-5 and H-1''. The carbon signal at δ 154.18 (C-7) displayed HMBC correlations with the proton signal at δ 4.80 (H-1'''), confirming 7-*O*-geranylation, which was corroborated by the NOE correlation between H-8 and H-1'''. Assignments of ¹H and ¹³C signals of **13** were made by 1D and 2D (¹H-¹H COSY, NOESY, HSQC, and HMBC) spectroscopic data. On the basis of this evidence, the structure of **13** was established to be *O,O*-digeranylpapaveroline (Scheme 2). The geometries of the disubstituted olefinic bonds (between 2'' and 3'' and between 2''' and 3''') were determined to be *E* on the basis of the NOE correlation between H-2'' and H-4'', and between 2''' and 3''', respectively.

HPLC of the reaction mixture in geranylation (Scheme 3) of 2, 3, 9, 10-tetrademethyltetrahydropalmatine (**14**) is shown in Figure 2 (II). The compounds corresponding to peaks **a**₅ and **b**₅ (Figure 2, II) (**15** and **16**) were purified by prep. HPLC. The molecular formula of compound **15** (peak **a**₅) was determined to be C₂₇H₃₄NO₄ by analysis of its HRSIMS ([M]⁺, *m/z* 436.2486), which indicates the presence of one

geranyl group. The ^1H NMR spectrum displays two aromatic proton singlets at δ 6.72 and 6.66, two aromatic proton doublets at δ 6.78 (1H, d, J = 8.0 Hz), 6.57 (1H, d, J = 8.0 Hz), methine and methylene protons at δ 4.58 (3H, brs), three methylene groups [δ 3.81 (1H), 3.54 (1H), 3.28 (1H), 3.18 (2H), 3.12 (1H)] arising from the protoberberine moiety and three methyl proton signals at δ 1.65 (3H, s), 1.59 (3H, s), and 1.58 (3H, s), two olefinic protons at δ 5.44 (1H, t, J = 8.0 Hz) and 5.08 (1H, brs), and three methylene groups [δ 4.08 (2H), 2.22 (2H), and 2.20 (2H)], assignable to the geranyl group. The NOE correlations between a methylene proton (δ 4.08, H-1') of the geranyl group and the protons at δ 4.58 (H-8 and/or H-13a) indicate that the geranyl group is attached to nitrogen. Based on these evidences, compound **15** was determined to be *N*-geranyl-2, 3, 9, 10-tetrademethyltetrahydropalmatinium salt. The ^{13}C NMR spectrum of **15** supports this structure, with signals corresponding to 26 (one carbon was overlapped) carbons including four protonated aromatic carbons (δ 119.69; 116.59x2; 114.52), eight quaternary carbons (δ 147.66; 146.25; 144.85; 143.60; 124.76; 121.90; 120.93; 114.80), four methylene carbons (δ 57.06; 51.66; 34.89; 23.75), and a methine carbon (δ 64.34) which arise from the tetrahydroprotoberberine structure, and two protonated olefinic carbons (δ 124.12; 111.74), two quaternary carbons (δ 152.82; 133.47), three methylene carbons (δ 59.93; 41.04; 26.97), three methyl groups (δ 25.78; 17.79; 16.94) assignable to the geranyl group. Assignments of ^1H and ^{13}C signals of **15** were made by 1D and 2D (^1H - ^1H COSY, NOESY, HSQC, and HMBC) spectroscopic data. On the basis of these data, the structure of **15** was established to be ($\pm$)-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalmatinium salt with the B/C-*cis* form as described later (Scheme 3).

The molecular formula of compound **16** (peak b₅) was determined to be $\text{C}_{27}\text{H}_{34}\text{NO}_4$ by analysis of its HRSIMS ($[\text{M}]^+$, m/z 436.2484), which indicates the presence of one geranyl group. The ^1H NMR spectrum displays two aromatic proton singlets at δ 6.84 and 6.71, two aromatic proton doublets at δ 6.85 and 6.77 (J = 8.2 Hz), a methine proton at δ 5.07 (1H, dd, J = 12.5, 5.0 Hz), and four methylene groups [δ 4.72 (1H, d, J = 15.5 Hz), 4.17 (1H, d, J = 15.5 Hz), 3.89 (1H), 3.83 (1H), 3.69 (1H), 3.26 (1H), 3.20 (1H), and 3.05 (1H)] which arise from the tetrahydroprotoberberine structure, and three methyl proton signals at δ 1.72 (3H, s), 1.66 (3H, s), and 1.33 (3H, s), two olefinic protons at δ 5.44 (1H, dd, J = 9.0, 5.5 Hz) and 5.14 (1H, brs), and three methylene groups [δ 3.86 (1H, m), 3.61 (1H, m), and δ 2.20 (4H, m)], assignable to the geranyl group. The NOE correlation between one of the methylene protons (δ 3.86, H-1') of the geranyl group and one of the methylene protons (δ 4.72, H-8) indicates that the geranyl group is attached to nitrogen. Based on these evidences, compound **16** was postulated to be the isomer of *N*-geranyl-2,3,9,10-tetrademethyltetrahydropalmatinium salt (**15**). Moreover, the ^{13}C NMR spectrum of **16** supports this structure, with signals corresponding to 27 carbons, including four protonated

aromatic carbons (δ 120.60; 116.84; 116.15; 113.45), eight quaternary carbons (δ 147.37; 146.63, 44.95; 143.66, 122.77; 122.43; 122.06; 115.38), four methylene carbons (δ 58.43; 57.62; 29.60; 24.48), and a methine carbon (δ 68.21) which arise from the tetrahydroprotoberberine structure, and two protonated olefinic carbons (δ 124.71; 114.42), two quaternary carbons (δ 153.83; 133.45), three methylene carbons (δ 46.96; 41.14; 27.10) and three methyl groups (δ 25.97; 17.89; 16.0) assignable to the geranyl group. The proton signals (H-1') at δ 3.86 and 3.61 display HMBC correlations with the carbons at δ 57.62 (C-8) and δ 58.43 (C-6), respectively, confirming *N*-geranylation, which was also suggested by the NOE correlation between H-8 and H-1'. Assignments of ^1H and ^{13}C signals of **16** were made by 1D and 2D (^1H - ^1H COSY, NOESY, HSQC, and HMBC) spectroscopic data. On the basis of these evidences, the structure of **16** was confirmed to be ($\pm$)-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalmatininium salt with the B/C-*trans* form as described below (Scheme 3).

Compounds **15** and **16** are stereoisomers of the B/C ring juncture. The chemical shifts of C-6 in **15** and **16** are 51.66 and 58.43 ppm, respectively. The upfield shift of C-6 in **15** compared with **16** is interpreted as being due to steric compression in the B/C-*cis* form because C (6)-H and C (13a)-C (13) bonds are 1, 3-diaxial in the B/C-*cis* form. The chemical shifts at C-13 in **15** and **16** are 34.89 and 29.60 ppm, respectively. The upfield shift of C-13 in **16** compared with **15** arises from steric interaction (1,3-diaxial) between C (13)-H and the *N*-(C-1') bonds in the B/C-*trans* form. Compounds **15** and **16** were established to be ($\pm$)-*cis*- and *trans*-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalmatininium salts (Scheme 3). The geometry of the disubstituted olefinic bond (between 2' and 3') was determined to be *E* in both compounds on the basis of the NOE correlation between H-2' and H-4'.

The HPLC of the reaction mixture in geranylation (Scheme 3) of 2,3,10,11-tetrademethylpseudo-tetrahydropalmatine (**17**) is shown in Figure 2 (III). Compound **18**, which corresponds to peak b_6 (Figure 2, III), was purified by prep. HPLC, although a_6 was not purified. The molecular formula of compound **18** was determined to be $\text{C}_{27}\text{H}_{34}\text{NO}_4$ by analysis of its HRSIMS ($[\text{M}]^+$, m/z 436.2487), which indicates the presence of one geranyl group. The ^1H NMR spectrum displays four aromatic proton singlets at δ 6.83, 6.81, 6.70, 6.55, a methine proton at δ 5.07 and four methylene groups [δ 4.39 (1H), 4.34 (1H), 3.85 (1H), 3.78 (1H), 3.63 (1H), 3.25 (1H), 3.15 (1H), and 3.04 (1H)] which arise from the protoberberine skeleton and three methyl proton signals at δ 1.73 (3H, s), 1.67 (3H, s), and 1.32 (3H, s), two olefinic protons at δ 5.44 (1H) and 5.12 (1H), and three methylene groups [δ 3.87 (1H), 3.64 (1H), and δ 2.20 (4H)], assignable to the geranyl group. From a comparison of the ^1H NMR spectrum with that of compounds **15** and **16**, compound **18** was postulated to be *N*-geranyl-2,3,10,11-tetrademethylpseudo-tetrahydropalmatininium salt with a B/C-*cis* or B/C-*trans* junction. The ^{13}C NMR spectrum of **18** displays signals corresponding to 27 carbons, including four protonated aromatic carbons

(δ 116.26; 116.15; 114.17; 113.46), eight quaternary carbons (δ 147.62; 146.69; 146.63; 147.39; 122.72; 122.53; 122.05; 118.26), four methylene carbons (δ 61.61; 58.27; 29.83; 24.38), a methine carbon (δ 68.55) arising from the tetrahydroprotoberberine structure, and two protonated olefinic carbons (δ 124.86; 111.41), two quaternary carbons (δ 152.91; 133.27), three methylene carbons (δ 46.69; 41.01; 27.04), and three methyl groups (δ 26.0; 17.91; 16.79) assignable to the geranyl group. Compound **18** was identified as ($\pm$)-*trans*-*N*-geranyl-2,3,10,11-tetrademethylpseudotetrahydropalmatinium salt (Scheme 3) from comparison of the chemical shifts of C-6 (δ 58.27) and C-13a (δ 68.55) with those (δ 51.66 and 64.34) in **15** (B/C-*cis*) and those (δ 58.43 and 68.21) in **16** (B/C-*trans*). The geometry of the disubstituted olefinic bond (between 2' and 3') was determined to be *E* on the basis of the NOE correlation between H-2' and H-4'. Assignments of ^1H and ^{13}C signals of **18** were made by 1D and 2D (^1H - ^1H COSY, NOESY, HSQC, and HMBC) spectroscopic data.

Antimicrobial activity.

The synthetic simple isoquinolines [salsolinol (**1**), *N*-geranylsalsolinol (**2**), *N,N*-digeranylsalsolinol (**3**), *N*-methylsalsolinol (**4**), *N,N*-dimethylsalsolinol (**5**), 7-*O*-geranylsalsolinol (**6**), 6-*O*-geranylsalsolinol (**7**), and 6,7-*O*-digeranylsalsolinol (**8**)], the synthetic 1-benzylisoquinolines [tetrahydropapaveroline (**9**), *N*-geranyl- and *N,N*-digeranyltetrahydropapaveroline (**10** and **11**), *N*-methylpapaveroline (**12**), and *O*, *O*-digeranyl-*N*-methylpapaveroline (**13**)], and the synthetic tetrahydroprotoberberines [2,3,9,10-tetrademethyltetrahydropalmatine (**14**), *cis*- and *trans*-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalmatinium salts (**15** and **16**), 2,3,10,11-tetrademethylpseudotetrahydropalmatine (**17**), and *trans*-*N*-geranyl-2,3,10,11-tetrademethylpseudotetrahydropalmatininium salt (**18**)] were tested against *Staphylococcus aureus* (Gram-positive) and *Escherichia coli* (Gram-negative) by the liquid dilution method. The minimum inhibitory concentrations (MIC) are presented in Table 1. The results for **1-5** have already been published.¹³

N-Geranylation increases the activity against both bacteria compared with salsolinol (**1**), *N*-methylsalsolinol (**4**), and *N,N*-dimethylsalsolinol (**5**), which are inactive. Notably, *N,N*-digeranylated salsolinol (**3**) displays significant activity (7.8 $\mu\text{g/mL}$) against *S. aureus*. Thus, according to these data, *N*-quaternization by *N*-geranylation (**3**), not simply *N*-alkylation (**5**), appears to be important for enhanced antimicrobial activity.

Table 1. Antibacterial activity of several 1isoquinoline-type alkaloids **1-18**

group	compound	MIC ($\mu\text{g/mL}$) ^a			
		<i>Staphylococcus aureus</i>		<i>Escherichia coli</i>	
		ATCC25923		ATCC25922	
simple isoquinolines	1 ^b	>	1000	>	1000
	2 ^b	$\geq$	62.5	$\geq$	1000
	3 ^b	$\geq$	7.8	$\geq$	31.3
	4 ^b	>	1000	>	1000
	5 ^b	>	1000	>	1000
	6		62.5	>	250
	7		62.5	>	250
	8		250	>	250
1-benzylisoquinolines	9	>	250	>	250
	10	$\geq$	250	>	250
	11	$\geq$	125	>	250
	12	>	250	>	250
	13	$\geq$	125	>	250
protoberberines	14	>	250	>	250
	15	$\geq$	250	>	250
	16	$\geq$	250	$\geq$	250
	17	>	250	>	250
	18	>	250	>	250
	Benzalkonium chliloride		3.9		15.7
	Benzethonium chloride		7.8		7.8

Enhancement of activity against *S. aureus* was observed in *O*-gerany isoquinolines (**6-8**). Enhanced activity was not observed in *N*- or *O*-geranylation of 1-benzylisoquinolines and tetrahydroprotoberberines.

Cytotoxicity evaluation.

The synthetic simple isoquinolines (**1-8**), 1-benzylisoquinolines (**9-13**), and tetrahydroprotoberberines (**14-18**) were assayed for *in vitro* cytotoxicity against five human tumor cell lines, including lung carcinoma (A-549), prostate carcinoma (DU145), epidermoid carcinoma of the nasopharynx (KB), a drug-resistant KB-subline (KBvin), and human promyelocytic leukemia (HL-60). The cytotoxicity data are given as an ED₅₀ value for each cell line, the concentration of a compound that caused a 50% reduction in absorbance at 562 nm relative to untreated cells using SRB¹⁰ and MTT¹⁶ and/or WST-8 assays (HL60 is a non-adherent cell line; therefore, the SRB assay could not be used with it), and are shown in Tables 2 and 3. The results for **1-5** have already been published.¹³

The parent salsolinol (**1**), *N*-methylsalsolinol (**4**), and *N,N*-dimethylsalsolinol (**5**) showed no activity in SRB and MTT assays, and *N*-geranylsalsolinol (**2**) showed either weak or no activity against all cell lines in both assays. In comparison, *N,N*-digeranylsalsolinol (**3**) showed especially increased activity against DU-145, KB, and HL-60 cell lines. Compound **3** exhibited the highest potency (1.2 µg/mL) against the HL-60 cell line, and also displayed high activity (0.77 µg/mL) against this cell line in the WST-8 assay (Table 3).¹⁷ Thus, *N*-geranylation, particularly digeranylation, increased cytotoxicity, while *N*-methylation, either mono or di, had no effect. The increase in cytotoxicity was found in *O*- and *O,O*-digeranyl compounds (**6-8**) compared with the parent *N,N*-dimethylsalsolinol (**5**) in the SRB assay, though activity of *O,O*-digeranyl compounds (**8**) was weaker than that of *N,N*-digeranylsalsolinol (**3**). Thus, from these data, *N*-quaternization by *N*-geranylation, not simply *N*-alkylation, appears to be important for enhanced cytotoxicity.

In 1-benzyltetrahydroisoquinoline, *N*- and *N,N*-digeranylations of tetrahydropapaveroline (**9**) increased remarkably the activity against three or four cell lines tested in the SRB assay. Compounds **10** and **11** showed a broad spectrum of activity. It was demonstrated that *N*-geranylation in the 1-benzyltetrahydroisoquinoline-type alkaloids contributes especially to the increase in cytotoxicity. The increase in cytotoxicity by *N,N*-digeranylations (**11**) compared with *N*-geranylation (**10**) was not observed to be distinct from that of the simple isoquinolines.

An increase in cytotoxicity was found in the *O,O*-digeranyl derivative (**13**) of papaveroline (**12**), except for the KBvin cell line in SRB and MTT assays. Compound **13** exhibited high potency (1.49 µg/mL) against the HL-60 cell line, and also displayed high activity (1.24 µg/mL) against this cell line in the WST-8 assay.¹⁷

Table 2. *In vitro* cytotoxic activity of several isoquinoline-type alkaloids **1-18** against various human tumor cell lines

group ^a	compound	cell line ^b				
		A-549	DU-145	KB	KBvin	HL-60
ED ₅₀ (μg/mL) ^c -SRB						
I	1^d	NA ^e	NA	NA	NA	ND ^e
	2^d	7.75	7.75	10.1	5.64	ND
	3^d	5.72	3.84	3.28	NA	ND
	4^d	> 20	> 20	> 20	> 20	ND
	5^d	> 20	> 20	> 20	> 20	ND
	6	> 20	12.4	12.8	> 20	ND
	7	7.12	13.9	7.70	> 20	ND
	8	8.90	11.5	7.60	> 20	ND
II	9	NA	NA	NA	NA	ND
	10	1.31	3.56	3.38	3.60	ND
	11	1.34	2.00	2.35	7.96	ND
	12	11.95	7.46	8.05	5.07	ND
	13	6.25	5.89	5.37	NA	ND
III	14	6.05	2.88	5.40	1.45	ND
	15	7.40	3.29	5.87	3.19	ND
	16	3.63	3.26	5.70	1.33	ND
	17	NA	NA	14.6	NA	ND
	18	9.68	2.31	2.90	NA	ND
Taxol ^f		2.91	1.91	3.10	> 850	ND
ED ₅₀ (μg/mL) ^c –MTT ^g						
I	1^d	NA	NA	NA	NA	NA
	2^d	NA	NA	NA	NA	NA

	3 ^d	15.8	3.28	5.70	NA	1.20

II	12	NA	NA	NA	NA	12.3
	13	7.50	5.26	6.43	NA	1.49

^aI: simple isoquinolines, II: 1-benzylisoquinolines, III: protoberberines

^bA-549: lung carcinoma, DU-145: prostate carcinoma, KB: epidermoid carcinoma of the nasopharynx, KBvin: drug-resistant, HL-60: human promyelocytic leukemia.

^cCytotoxicity as ED₅₀ for each cell line, the concentration of compound that causes a 50% reduction in adsorbance at 562 nm relative to untreated cells using the SRB or MTT assay. Pure compound is considered to be significantly active when its ED₅₀ < 4.0 µg/mL.

^dThese data have already been prepared.¹³ ^eNA: no activity (if it does not have 50% inhibition at 20 µg/mL, we suggest it has no activity); ND: not determined; ^fng/mL; ^gDifferent time of treatment (because of long doubling time in HL-60): 24 hr for A-549, DU-145, KB, and KBvin; 72 hr for HL-60 in MTT assay

In 2,3,9,10-tetrademethyltetrahydropalmatine (**14**), an increase in cytotoxicity by *N*-geranylation (**15**, **16**) of the stereostructure was not observed in almost all cell lines, while in the *N*-geranyl derivative (**18**) with a B/C-*trans* junction of 2,3,10,11-tetrademethylpseudotetrahydropalmatine (**17**), the activity increased, except for the KBvin cell line. Contrary to this, compounds **15** and **16** displayed higher activity than **18** against the HL-60 cell line.

Comparing the activity between the compounds and the cell lines, *N*- and *N,N*-geranyl derivatives (**10** and **11**) of the 1-benzyltetrahydroisoquinolines and *N*-geranyl compound (**16**, tetrahydroprotoberberine) with a B/C-*trans* junction showed high potency (1.31-3.63 µg/mL) in three or four cell lines. The *N,N*- and *N*-geranylated compounds (**3**, simple isoquinoline and **18**, tetrahydroprotoberberine) displayed high activity (2.31-3.84 µg/mL) in DU145 and KB cell lines. 2,3,9,10-Tetrademethyltetrahydroprotoberberine (**14-16**) exhibited high potency (1.33-3.19 µg/mL) in the KBvin cell line, independent of the presence of the geranyl group. In both MTT and WST-8 assays, only two *N,N*- and *O,O*-geranylated compounds (**3**, simple isoquinoline and **13**, 1-benzylisoquinoline) displayed high activity in the HL-60 cell line. It was suggested that the structures of the test samples had a strong effect on the HL-60 cell line.

Table 3. *In vitro* cytotoxic activity of several isoquinolines-type alkaloids **1-4** and **9-18** against HL-60

group	compound	IC ₅₀ value (μg/mL)-WST-8
simple isoquinolines	1	7.17
	2	7.33
	3	0.77
	4	5.09
1-benzylisoquinolines	9	6.99
	10	4.78
	11	7.32
	12	3.68
	13	1.24
protoberberines	14	> 20
	15	8.05
	16	12.38
	17	6.15
	18	16.3

Inhibitory effects on EBV-EA induction.

The Epstein-Barr virus early antigen (EBV-EA) activation assay is considered to be an effective indicator for the evaluation of anti-tumor-promoting activity.¹¹ The inhibitory effects of simple isoquinolines (**1-8**), 1-benzylisoquinolines (**9-13**), and tetrahydroprotoberberines (**14-18**) on EBV-EA activation induced by 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in Raji cells were examined as a primary screening of anti-tumor-promoting activity.

Table 4. Inhibitory effects of several isoquinoline-type alkaloids **1–18** on TPA Induced EBV-EA activation (100%)^a

group	compound	1000	concentration (mol ratio/32 pmol TPA)			
			500	100	10	IC ₅₀ ^b
			% to control (% viability)			
simple isoquinolines	1^c	12.0 (60)	37.6	79.0	100	384
	2^c	3.1 (70)	24.3	71.6	97.4	350
	3^c	0 (70)	20.6	69.3	91.7	296
	4^c	9.3 (60)	36.8	78.8	100	372
	5^c	8.7 (60)	35.1	78.0	100	369
	6	8.9 (60)	36.8	69.8	98.7	371
	7	8.0 (60)	36.1	69.0	98.0	369
	8	5.3 (60)	32.6	67.3	96.5	335
1-benzylisoquinolines	9	13.9 (60)	37.5	76.9	100	387
	10	11.8 (60)	36.1	75.4	100	380
	11	8.9 (60)	35.0	74.3	100	369
	12	15.0 (60)	39.2	80.6	100	410
	13	9.1 (60)	31.2	72.4	100	323
protoberberines	14	0 (60)	25.8	76.8	96.9	321
	15	0 (60)	23.2	74.2	94.3	307
	16	0 (60)	23.7	74.8	94.7	308
	17	0 (60)	23.7	71.5	94.0	305
	18	0 (60)	23.2	71.1	93.8	303
	Ginsenoside-Rg1	0 (80)	32.5	72.6	91.0	310
	β-Carotene	9.1 (60)	34.3	82.7	100	400

^aValues represent percentages relative to the positive control value. TPA (32 pmol, 20 ng) = 100%. Values in parentheses are viability percentages of Raji cell. ^bIC₅₀ represents the mol ratio to TPA that inhibits 50% of positive control (100%) activated with 32 pmol of TPA.

^cThese data have been published.¹³

The inhibitory effects of the test compounds on TPA-induced EBV-EA activation, their effects on the viability of Raji cells, and the 50% inhibitory concentration (IC₅₀) values are shown in Table 4. The results for **1-5** have already been published.¹³

All simple isoquinolines (**1-8**) displayed stronger inhibition (IC₅₀ 296-384) than that of the reference β -carotene (IC₅₀ 400), which has been studied extensively in cancer chemoprevention using animal models.¹⁸ The inhibitory activity was more increased by geranylation than by methylation on nitrogen (compared with **3** and **5**). Therefore, *N*-geranylation but not *N*-dimethylation appears to be important for enhanced activity. *N,N*-Digeranylsalsolinol (**3**) displayed the strongest inhibition (IC₅₀ 296), and its activity was higher than that of ginsenoside-Rg1, which is known as a strong anti-tumor-promoter.¹⁹

The 6,7-*O*-digeranylated derivative (**8**) had increased activity (IC₅₀ 335) compared with the parent compound (**5**), though 6- and 7-*O*-geranylation (**6** and **7**) scarcely affected the activity. Thus, these compounds, especially *N,N*- and *O,O*-digeranylated derivatives, appear to be useful leads for further development of potential cancer chemopreventive agents.

There was little increase in inhibition by *N*-, and *N,N*-geranylation (**10** and **11**) of tetrahydropapaveroline (**9**). Increased inhibition (IC₅₀ 323) was observed in *O*, *O*-geranylation (**13**) of papaveroline (**12**). All tetrahydroprotoberberines (**14-18**) displayed strong inhibition (IC₅₀ 303-321) comparable to ginsenoside-Rg1 (IC₅₀ 310), independent of whether the compound has the geranyl group or not. They might be valuable antitumor promoters. In 2, 3, 9, 10-tetrademethyltetrahydropalmatine (**14**), there was little increase in inhibition by *N*-geranylation (**15**, **16**) independent of the stereostructure.

In simple isoquinolines and 1-benzylisoquinolines, digeranylated derivatives (**3**, **8**, and **13**) displayed potent activity, suggesting that relative lipophilicity of the geranyl groups may contribute to the inhibitory effect.

Free radical scavenging activity.

Several human illnesses, such as cancer, diabetes, atherosclerosis, etc., can be linked to the damaging action of reactive free radicals.²⁰ The ability of three types of compounds (**1-18**) to scavenge 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals was examined; the results are presented in Table 5. The results for **1-3** have already been published.¹³ To evaluate the free radical scavenging activity of these compounds, the concentration required to scavenge DPPH free radicals by 50% (SC₅₀) was determined. The antioxidant α -tocopherol was used as a reference compound. Compounds **1-3** displayed similar potency and were more active than α -tocopherol. 6-*O*- or 7-*O*-Geranylation (**6** or **7**) of **5** reduced the activity and 6,7-*O*-digeranylation (**8**) further reduced the activity.

Table 5. Radical scavenging activity of several isoquinoline-type alkaloids **1-18**

group	compound	SC ₅₀ (μM) ^a
simple isoquinolines	1 ^b	12.0
	2 ^b	17.0
	3 ^b	11.5
	4	32.1
	5	31.3
	6	40.7
	7	41.1
	8	57.7
1-benzylisoquinolines	9	2.64
	10	7.81
	11	6.47
	12	2.95
	13	9.94
protoberberines	14	5.53
	15	8.39
	16	3.81
	17	6.04
	18	5.36
	α-tocopherol	24.3

^aThe compound concentration showing radical scavenging efficacy of 50% was defined as SC₅₀.^bThese data have already been prepared.¹³

All 1-benzyltetrahydroisoquinolines (**9-13**) are more active than α -tocopherol. *N*-Geranylation (**10, 11**) of 1-benzyltetrahydroisoquinoline (**9**) reduced the activity. The activity also decreased by *O,O*-digeranylation (**13**) of papaveroline (**12**). All tetrahydroprotoberberines (**14-18**) proved to be more active than α -tocopherol; increased activity by *N*-geranylation was small.

In all three types of isoquinoline alkaloids, the activity was reduced by *N*- or *O*-geranylation. Obviously the phenolic hydroxyl groups on the aromatic rings strongly influenced the activity, without an affect of the geranyl group.

Antimalarial activity.

The simple isoquinolines (**1-3**), 1-benzylisoquinolines (**12, 13**), and tetrahydroprotoberberines (**14, 16-18**) were tested *in vitro* against human malaria parasite, *Plasmodium falciparum* FCR-3. The antimalarial activity of each compound was determined as a percentage of reduction compare of control. The compound concentration required to inhibit cell growth by 50% was expressed as EC_{50} . To evaluate the toxicity of the compounds for mammalian cells, the concentration causing a 50% growth reduction (IC_{50}) of mouse mammary FM3A cells, a model of the host, was determined. The IC_{50}/EC_{50} ratios for the compounds were calculated as an evaluation of antimalarial activity. The results are presented in Table 6. In three types of isoquinoline derivatives, *N*-geranylation increased the inhibitory activity; however, the geranylated derivatives of the simple isoquinolines and 1-benzylisoquinolines showed only slight inhibitory activity and no selectivity. Only *N*-geranyl derivatives (**16** and **18**) of the tetrahydroprotoberberines inhibited *P. falciparum* with EC_{50} values in the order of 10^{-7} M. This is an increase antimalarial activity compared with the parent compounds (**14** and **17**), and their selectivity indexes were > 15 . Compounds **16** and **18** were potent antimalarial agents with higher selectivity indexes compared with the other test compounds.

In addition, *N*-geranyl derivatives, **16** and **18**, it is noted that the selectivity of the compounds (selectivity; >15) was comparable to that of mefloquine (selectivity; 90). It means that these compounds have safety for human clinical treatment of malaria if these compounds developed new antiamalrial drug.

Table 6. *In vitro* antimalarial activity of several isoquinoline-type alkaloids **1-3**, **12-14**, and **16-18**

group	compound	50 % inhibitory concentration (μM) ^a		selectivity index ^b
		<i>Plasmodium falciparum</i> FCR-3 EC ₅₀ (growth %)	Mouse mammary cells FM3A IC ₅₀ (growth %)	
simple isoquinolines	1	>27 (100 %)	9.0	-
	2	5.3	0.08	-
	3	3.4	0.45	-
1-benzylisoquinolines	12	5.1	2.9	-
	13	3.6	1.5	-
protoberberines	14	>17 (100 %)	>8.3 (73 %)	-
	16	0.33	>4.9 (69 %)	>15
	17	9.5	8.1	-
	18	0.53	>7.7 (69 %)	>15
	Mefloquine	0.032	2.9	91

^aThe 50 % inhibitory concentration was defined by comparison with drug-free controls incubated under same condition.

^bIn vitro selectivity index was estimated from the ratio (IC₅₀ / EC₅₀) of the drug concentrations necessary to inhibit the growth rate of cells to 50 % of the growth value between the malaria parasites and mouse mammary FM3A cells which served as a model host.

Table 7. Anti-HIV activity of several isoquinoline-type alkaloids **1-18**

group	compound	IC ₅₀ (μg/mL) ^a	EC ₅₀ (μg/mL) ^b
simple isoquinoline type	1 ^c	>25	>2.5
	2 ^c	20.23	>2.5
	3 ^c	10.68	>2.5
	4	>25	>2.5
	5	>25	>25
1-benzylisoquinoline type	9	19.69	>2.5
	10	24.59	>2.5
	11	18.02	>2.5
	12	>25	>2.5
	13	17.95	>2.5
protoberberine type	14	>25	>2.5
	15	19.84	>2.5
	16	>25	>25
	17	18.13	22.54
	18	>25	>25
AZT ^d		500	0.014

^aThe agent concentration that inhibited H9 cell growth by 50%. ^bThe agent concentration that inhibited viral replication in H9 cell by 50%. ^cThese data have already been prepared.¹³

^dAzidothymidine

Anti-HIV activity.

The isoquinoline alkaloids (**1-4** and **9-18**) were tested against HIV-1 replication in H9 lymphocytes in order to evaluate their anti-HIV activity. However, none of them displayed anti-HIV activity (Table 7). Interestingly, results in the anti-HIV assay did not parallel those in the antimicrobial and cytotoxicity assays.

Conclusions.

In summary, three types of isoquinoline alkaloids (**1-18**) were tested for antimicrobial, cytotoxic, anti-malarial, anti-oxidant, and anti-HIV activities, as well as inhibitory activity against Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in Raji cells. *N*- or *O*-Geranylation contributed to increased potency in four types of activities except anti-HIV and anti-oxidant. *N,N*-Geranylation of salsolinol (simple isoquinoline, **1**) strongly increased the potency in antimicrobial activity. *N,N*- and *N*-Geranylations of tetrahydropapaveroline (1-benzylisoquinoline, **9**) strongly enhanced cytotoxic activity. *N,N*-Geranylation of **1** and *N*-geranylation of **17** (2,3,10,11-oxygenated protoberberine) increased the same activity to a lesser extent. *N,N*-Geranylation of **1** and *O,O*-geranylation of papaveroline (1-benzylisoquinoline, **11**) strongly increased cytotoxic activity against the HL-60 cell line. *N,N*-Geranylsalsolinol (**3**) showed potent inhibitory effects on EBV-EA induction compared with those of the parent compound (**1**). *O,O*-Geranylation of **5** (simple isoquinoline) and *N,N*-geranylation of **11** (1-benzylisoquinoline) enhanced the inhibitory activity. The protoberberines (**14-18**) tested also displayed strong inhibitory activity. *N*-Geranylation of 2,3,9,10- and 2,3,10,11-oxygenated protoberberines increased the antimalarial activity. Among the tested biological activities of the isoquinolines **1-18**, *N,N*-geranylation of salsolinol (**1**) strongly increased potency in three assays, antimicrobial and cytotoxic activities and inhibitory effects on EBV-EA induction, while *N*-geranylation increased the same activities to a lesser extent. However, *N,N*- and *N*-methylation did not increase the activities in these assays. These simple *N*-geranylated isoquinolines also have free radical scavenging activity. These findings indicate that the *N*-geranyl group plays an important role in mediating these biological activities.

Compound **3** shows antimicrobial, cytotoxic, and inhibitory effects on EBV-EA induction, compounds **10**, **11**, **13**, and **18** are cytotoxic, **8**, **13**, and **14-18** inhibit EBV-EA induction, and **16** and **18** display antimalarial activity. In the present studies, we have identified new biologically active *N*- or *O*-geranylated isoquinolines, which may be considered as lead structures for developing potential chemotherapeutic agents. It was first suggested that the addition of a geranyl residue to isoquinoline skeletons may contribute to the enhancement of the biological activities of isoquinoline alkaloids.

EXPERIMENTAL

General procedures. Conventional ^1H NMR, NOESY, COSY, HMBC, and HMQC spectra were obtained on a Varian VXR-500 spectrometer (^1H : 500 MHz) using CD_3OD solvent, except where noted, with TMS as int. standard. ^{13}C NMR and DEPT spectra were measured on a Varian VXR-500 spectrometer (125 MHz). Mass spectra were determined on a Hitachi M-4100 instrument at 75 eV. The secondary ion mass spectra (SIMS) were measured using glycerol as matrix. HPLC and prep. HPLC analyses were performed using a Hitachi M-6200 intelligent pump (1 mL/min) and Hitachi M-6250 or Jasco PU-2089 intelligent pump (6 mL/min), respectively, and a Hitachi L-4000 UV detector (280 nm). Cosmosil 5C₁₈-AR reversed-phase column of small (4.6 i.d. X 150 mm) and large (20 i.d. X 250 mm) sizes were used for HPLC and prep. HPLC, respectively. Analyses with a Hitachi HPLC system were made using a solvent system, (A) 0.1M NH_4OAc (0.05% TFA) / (B) MeOH (0.05% TFA) under the following gradient conditions: A/B, initial (75/25), 10 min (50/50), 30 min (20/80) or initial (80/20), 30 min (0/100) or initial (80/20), 20 min (0/100) (flow rate 1 mL/min). Prep. HPLC analyses for purification were performed using a solvent system, (A) H_2O (0.05% TFA) / (B) MeOH (0.05% TFA) under the following gradient conditions: A/B 50/50 to 0/100, 30 to 60 min (flow rate 6 mL/min). ($\pm$)-Tetrahydropapaverine hydrochloride and azidothymidine (AZT) were purchased (Sigma). ($\pm$)-Salsolinol (**1**),⁸ ($\pm$)-carnegine,⁹ ($\pm$)-*N*-methylpapaveroline (**11**),⁹ ($\pm$)-2,3,9,10-tetrademethyl-tetrahydropalmatine (**14**),⁹ and ($\pm$)-2, 3, 10, 11-tetrademethylpseudotetrahydropalmatine (**17**)⁹ have previously been prepared.

Optimized geometry and molecular orbital were calculated by the DFT Method (Density Function Theory) using the Materials Studio DMol3 package of Accelrys Inc.^{14,15} First, optimized geometry was obtained using the Perdew-Wong LDA functional (PWC)²¹ and double numerical plus d-functional (DND) basis set. Second, the optimized geometry obtained was further calculated for molecular orbitals using the Becke exchange plus Lee-Young-Parr correlation (BLYP)^{22, 23} and the double numerical plus polarization (DNP) basis set.

Preparations of ($\pm$)-*N*- and ($\pm$)-*N,N*-geranylsalsolinol (2** and **3**).** To a stirred suspension of sodium hydride (245 mg, 10.2 mmol) in DMF (15 mL) at room temperature under N_2 ($\pm$)-salsolinol hydrochloride⁸ (**1**, 1 g, 4.65 mmol) was added by portions followed by a catalytic amount of hydroquinone. The mixture was stirred for 30 min. Geranyl bromide (953 mg, 4.39 mmol) was added dropwise and the mixture was stirred for 2 h. NaH (245 mg, 10.2 mmol) and geranyl bromide (953 mg, 4.39 mmol) were added again, and the mixture was stirred for 2 h. After decomposition of excess NaH with MeOH (1 mL), the mixture was poured onto ice-water and extracted with Et_2O followed by CHCl_3 . Et_2O and CHCl_3 were separately dried and evaporated. The CHCl_3 extract was subjected to prep.

HPLC [0.1M NH₄OAc (0.05% TFA) / MeOH (0.05% TFA) (A/B) initial 60/40, 0/100 (30 min)] to give (±)-*N*-geranylsalsolinol (**2**, 205.7 mg, yield 10.3%) and (±)-*N,N*-geranylsalsolinol (**3**, 329.9 mg; yield 12.6%) as trifluoroacetate. **2**: SIMS m/z [M + H]⁺ 316; HRMS m/z [M + H]⁺ 316.2257 (C₂₀H₃₀NO₂ requires 316.2271). **3**: SIMS m/z [M]⁺ 452; HRMS m/z [M]⁺ 452.3527 (C₃₀H₄₆NO₂ requires 452.3523). The ¹H and ¹³C NMR spectral data of these compounds have been previously presented.¹³

Preparation of (±)-*N*-methylsalsolinol (4**).** Carnegine-HCl (500 mg, 1.94 mmol) in 47% HBr (2 ml) was refluxed for 2 h at 130° in an oil bath. The solvent was evaporated *in vacuo*, the residue in MeOH was crystallized to give (±)-*N*-methylsalsolinol-HBr (**4**, 398.5 mg, yield 64.8%). SIMS m/z [M + H]⁺ 194; HRMS m/z [M + H]⁺ 194.1201 (C₁₁H₁₆NO₂ requires 194.1176). The ¹H and ¹³C NMR spectral data of **4** have been previously presented.¹³

Preparation of (±)-*N,N*-dimethylsalsolinol (5**).** A solution of carnegine-HCl (3.1 g, 12.06 mmol) and CH₃I (1 ml) in MeOH (25 ml) and (Me)₂CO (25 ml) in a glass-stoppered bottle was heated for 75 min at 110 °C in a oil bath. The solvent was evaporated *in vacuo*, the residue was crystallized in (Me)₂CO-Et₂O to give *N*-methylcarnegine iodide (4.75 g, yield 86.5%). The iodide (3.8 g) in 47% HBr (10 ml) was refluxed for 1 h at 140 °C in an oil bath. The solvent was evaporated *in vacuo*, the residue was crystallized in (Me)₂CO-Et₂O to give (±)-*N,N*-dimethylsalsolinol bromide (**5**, 2.97 g, yield 98.5%). SIMS m/z [M]⁺ 208; HRMS m/z [M]⁺ 208.1350 (C₁₂H₁₈NO₂ requires 208.1336). The ¹H and ¹³C NMR spectral data of **5** have been previously presented.¹³

Preparations of (±)-7-*O*-geranyl-, (±)-6-*O*-geranyl-, and (±)-6,7-*O*-digeranyl-*N,N*-dimethylsalsolinol (6-8**).** To a stirred suspension of NaH (260 mg, 10.8 mmol) in DMF (15 mL) at rt under N₂ (±)-*N,N*-dimethylsalsolinol hydrobromide (**5**, 1 g, 3.47 mmol) was added portionwise followed by a catalytic amount of hydroquinone. The mixture was stirred for 30 min. Geranyl bromide (1 g, 4.61 mmol) was added dropwise and the whole mixture was stirred for 3 h. After decomposition of excess NaH with MeOH (1 mL), the mixture was poured onto ice-water and extracted with CHCl₃. The combined organic layer was dried and evaporated. The CHCl₃ extract was subjected to prep. HPLC [0.1M NH₄OAc (0.05% TFA)/MeOH (0.05% TFA) (A/B) initial 100/0, 0/100 (540 min)] to give (±)-7-*O*-geranyl-*N,N*-dimethylsalsolinol (**6**, 102.2 mg, yield 7.7%), (±)-6-*O*-geranyl-*N,N*-dimethylsalsolinol (**7**, 98.8 mg, yield 7.4%) and (±)-6,7-*O*-digeranyl-*N,N*-dimethylsalsolinol (**8**, 154.2 mg, yield 8.9%) as trifluoroacetates. **6**: ¹H NMR (500 MHz, CD₃OD) δ 6.68 (1H, s, H-5), 6.74 (1H, s, H-8), 5.48 (1H, t, *J* = 6.5 Hz, H-2'), 5.09 (1H, t, *J* = 6.5 Hz, H-6'), 4.62 (2H, d, *J* = 6.5 Hz, H-1'), 4.57 (1H, q, *J* = 6.5 Hz, H-1), 3.77 (1H, dt, *J* = 12.5, 8.0 Hz, Hax'-3), 3.55 (1H, dt, *J* = 12.5, 5.0 Hz, Heq'-3), 3.17 (3H, s, ax'NMe), 3.14 (3H, s, eq'NMe), 3.08 (2H, m, H-4), 2.12 (2H, m, H-5'), 2.09 (2H, m, H-4'), 1.75 (3H, s, 3'-Me), 1.69 (3H, d, *J* = 6.5 Hz, Me-1), 1.65 (3H, s, 8'), 1.59 (3H, s, 7'-Me); ¹³C NMR (125 MHz,

CD₃OD) δ 148.79 (C-6), 147.83 (C-7), 142.30 (C-3'), 132.63 (C-7'), 124.90 (C-6'), 124.39 (C-1a), 122.17 (C-4a), 120.94 (C-2'), 116.01 (C-5), 113.25 (C-8), 69.51 (C-1), 67.06 (C-1'), 56.86 (C-3), 51.50 (eq'NMe), 50.11 (ax'NMe), 40.61 (C-4'), 27.41 (C-5'), 25.84 (C-8'), 24.30 (C-4), 18.63 (C-1-Me), 17.72 (7'-Me), 16.69 (3'-Me); SIMS m/z [M]⁺ 344; HRMS m/z [M + H]⁺ 344.2606 (C₂₂H₃₄NO₂ requires 344.2588), m/z [M-C₁₀H₁₆]⁺ 208.1355 (C₁₂H₁₈NO₂ requires 208.1338); **7**: ¹H NMR (500 MHz, CD₃OD) δ 6.79 (1H, s, H-5), 6.66 (1H, s, H-8), 5.50 (1H, m, H-2'), 5.10 (1H, m, H-6'), 4.63 (2H, d, J = 6.5 Hz, H-1'), 4.55 (1H, q, J = 6.5 Hz, H-1), 3.78 (1H, dt, J = 12.5, 7.5 Hz, Hax'-3), 3.56 (1H, dt, J = 12.5, 6.0 Hz, Heq'-3), 3.17 (3H, s, ax'NMe), 3.13 (3H, s, eq'NMe), 3.12 (2H, m, H-4), 2.12 (2H, m, H-5'), 2.07 (2H, m, H-4'), 1.75 (3H, s, 3'-Me), 1.67 (3H, d, J = 6.5 Hz, Me-1), 1.65 (3H, s, Me-8'), 1.60 (3H, s, 7'-Me); ¹³C NMR (125 MHz, CD₃OD) δ 148.62 (C-6), 147.90 (C-7), 142.26 (C-3'), 132.63 (C-7'), 124.90 (C-6'), 124.39 (C-1a), 122.17 (C-4a), 120.94 (C-2'), 116.01 (C-5), 113.25 (C-8), 69.36 (C-1), 66.86 (C-1'), 57.19 (C-3), 51.58 (eq'NMe), 49.80 (ax'NMe), 40.62 (C-4'), 27.39 (C-5'), 25.86 (C-8'), 24.51 (C-4), 18.36 (C-1-Me), 17.74 (7'-Me), 16.67 (3'-Me); SIMS m/z [M]⁺ 344; HRMS m/z [M + H]⁺ 344.2603 (C₂₂H₃₄NO₂ requires 344.2588), m/z [M-C₁₀H₁₆]⁺ 208.1317 (C₁₂H₁₈NO₂ requires 208.1338); **8**: ¹H NMR (500 MHz, CD₃OD) δ 6.83 (1H, s, H-5), 6.79 (1H, s, H-8), 5.48 (2H, m, H-2', H-2''), 5.10 (2H, m, H-6', H-6''), 4.59 (2H, m, H-1''), 4.58 (2H, m, H-1'), 4.54 (1H, q, J = 6.5 Hz, H-1), 3.79 (1H, dt, J = 12.5, 8.0 Hz, Hax'-3), 3.57 (1H, dt, J = 12.5, 5.0 Hz, Heq'-3), 3.17 (3H, s, ax'NMe), 3.15 (3H, s, eq'NMe), 3.14 (2H, m, H-4), 2.12 (4H, m, H-5', H-5''), 2.07 (4H, m, H-4', H-4''), 1.742 (3H, s, 3''-Me), 1.736 (3H, s, 3'-Me), 1.69 (3H, d, J = 6.5 Hz, Me-1), 1.66 (6H, s, 8', 8''), 1.60 (6H, s, 7'-Me, 7''-Me); ¹³C NMR (125 MHz, CD₃OD) δ 150.79 (C-6), 149.78 (C-7), 142.58 (C-3''), 142.56 (C-3'), 132.68 (C-7'), 125.09 (C-1a), 124.96 (C-6'), 122.33 (C-4a), 120.94 (C-2''), 120.85 (C-2'), 115.05 (C-5), 114.41 (C-8), 69.60 (C-1), 67.38 (C-1'), 67.04 (C-1''), 56.83 (C-3), 51.55 (eq'NMe), 50.25 (ax'NMe), 40.66 (C-4', C-4''), 27.48 (C-5'), 27.44 (C-5''), 25.93 (C-8'), 24.56 (C-4), 18.63 (C-1-Me), 17.81 (7'-Me), 16.77 (3'-Me), 16.74 (3''-Me); SIMS m/z [M]⁺ 480; HRMS m/z [M]⁺ 480.3858 (C₃₂H₅₀NO₂ requires 480.3837), m/z [M-C₁₀H₁₆]⁺ 344.2586 (C₂₂H₃₄NO₂ requires 344.2588).

Preparation of (±)-tetrahydropapaveroline (9). A solution of (±)-tetrahydropapaverine hydrochloride (Sigma, 2 g, 5.26 mmol) in 47% HBr (10 ml) was refluxed for 2.5 h. The solvent was evaporated *in vacuo*. The crystalline product was recrystallized from MeOH to give (±)-tetrahydropapaveroline hydrobromide **9** (1.84 g, yield 95.1%) which was identified by comparing its ¹H NMR and HPLC with data of an authentic sample.

Preparations of (±)-N- and (±)-N,N-digeranyltetrahydropapaveroline (10 and 11). To a stirred suspension of NaH (65 mg, 2.71 mmol) in DMF (15 mL) at rt under N₂ (±)-tetrahydropapaveroline hydrobromide (**9**, 1 g, 2.72 mmol) was added portionwise followed by a catalytic amount of

hydroquinone. The mixture was stirred for 30 min. Geranyl bromide (590 mg, 2.72 mmol) was added dropwise, and the mixture was stirred for 10 h. Geranyl bromide (295 mg, 1.36 mmol) was added dropwise and the mixture was further stirred for 12 h. After decomposition of excess NaH with MeOH (1 mL), the mixture was poured onto ice-water and extracted with Et₂O followed by CHCl₃. The Et₂O and CHCl₃ phases were separately dried and evaporated. The CHCl₃ extract was subjected to prep. HPLC [0.1M NH₄OAc (0.05% TFA)/MeOH (0.05% TFA) (A/B) initial 80/20, 0/100 (60 min)] to give (±)-*N*-geranyltetrahydropapaveroline (**10**, 274 mg, yield 18.7%) and (±)-*N,N*-digeranyltetrahydropapaveroline (**11**, 175 mg, yield 9.5%) as trifluoroacetate. **10**: ¹H NMR (500 MHz, CD₃OD) δ 6.75 (1H, d, *J* = 8.5 Hz H-5'), 6.65 (1H, s, H-5), 6.58 (1H, brs, H-2'), 6.50 (1H, brd, *J* = 8.5 Hz, H-6'), 6.18 (1H, s, H-8), 5.26 (1H, m, H-2''), 5.12 (1H, m, H-6''), 4.42 (1H, t, *J* = 6.5 Hz, H-1), 3.83 (1H, dd, *J* = 13.0, 8.5 Hz, H-1'), 3.71 (1H, m, H-1''), 3.68 (1H, m, H-3), 3.38 (1H, m, H-3), 3.14 (1H, m, H-9), 3.04 (1H, m, H-9), 2.97 (2H, m, H-4), 2.18 (4H, s, H-4'', H-5''), 2.12 (2H, m, H-5'), 2.07 (2H, m, H-4'), 1.70 (3H, s, Me-8'), 1.64 (3H, s, 7''-Me), 1.57 (3H, s, 3''-Me); ¹³C NMR (125 MHz, CD₃OD) δ 149.65 (C-3'), 147.30 (C-6), 146.92 (C-3'), 146.04 (C-4'), 145.65 (C-7), 133.29 (C-7'), 127.63 (C-1'), 124.56 (C-6''), 121.93 (C-4a), 121.87 (C-1^a, C-6'), 117.67 (C-2'), 116.76 (C-5'), 116.12 (C-5), 115.75 (C-8), 114.15 (C-2''), 63.01 (C-1), 51.86 (C-1'), 44.80 (C-3), 40.74 (C-4'', C-9), 27.14 (C-5'), 25.94 (C-8'), 22.90 (C-4), 17.84 (7''-Me), 16.80 (3''-Me); SIMS *m/z* [M + H]⁺ 424; HRMS *m/z* [M + H]⁺ 424.2494 (C₂₆H₃₄NO₄ requires 424.2482); **11**: ¹H NMR (500 MHz, CD₃OD) δ 6.67 (1H, d, *J* = 8.0 Hz H-5'), 6.64 (1H, s, H-5), 6.38 (1H, brs, H-2'), 6.30 (1H, dd, *J* = 8.0, 2.0 Hz, H-6'), 5.89 (1H, s, H-8), 5.61 (1H, d, *J* = 7.0 Hz H-2''), 5.42 (1H, t, *J* = 7.0 Hz, H-2''), 5.15 (1H, m, H-6'''), 4.99 (1H, m, H-6''), 4.42 (1H, dd, *J* = 9.5, 3.0 Hz, H-1), 4.20 (1H, dd, *J* = 14.5, 7.0 Hz, H-1'''), 4.13 (1H, dd, *J* = 14.5, 7.0 Hz, H-1''), 3.96 (1H, dd, *J* = 14.5, 9.0 Hz, H-1'), 3.78 (1H, dd, *J* = 14.5, 6.0 Hz, H-1'), 3.68 (1H, m, Hax'-3), 3.53 (1H, m, Heq'-3), 3.45 (1H, dd, *J* = 13.5, 3.5 Hz, H-9), 2.88 (1H, dd, *J* = 13.5, 9.5 Hz, H-9), 2.97 (2H, m, H-4), 2.28 (4H, s, H-4''', H-5'''), 2.18 (4H, s, H-4'', H-5''), 2.07 (2H, m, H-4'), 1.85 (3H, s, 3'''-Me), 1.69 (3H, s, Me-8'), 1.68 (3H, s, Me-8''), 1.65 (3H, s, 7'''-Me), 1.62 (3H, s, 7''-Me), 1.46 (3H, s, 3'-Me); ¹³C NMR (125 MHz, CD₃OD) δ 151.18 (C-3'), 150.09 (C-3'''), 147.52 (C-6), 146.65 (C-3'), 145.82 (C-4'), 145.24 (C-7), 133.37 (C-7'), 133.32 (C-7'''), 127.88 (C-1'), 124.70 (C-6''), 124.65 (C-6'''), 121.42 (C-4a), 122.52 (C-1a), 122.25 (C-6'), 118.04 (C-2'), 116.51 (C-5'), 115.85 (C-5), 116.81 (C-8), 112.11 (C-2'', C-2'''), 70.72 (C-1), 58.30 (C-1'''), 55.79 (C-1'), 52.01 (C-3), 41.06 (C-4'', C-4'''), 38.32 (C-9), 27.14 (C-5'''), 27.05 (C-5''), 25.98 or 25.99 (C-8'' or C-8'''), 24.0 (C-4), 17.87 or 17.89 (7''-Me or 7'''-Me), 17.28 (3'''-Me), 16.90 (3'-Me); SIMS *m/z* [M]⁺ 560; HRMS *m/z* [M]⁺ 560.3746 (C₃₆H₅₀NO₄ requires 560.3746), *m/z* [M-C₁₀H₁₆]⁺ 424.2498 (C₂₆H₃₄NO₂ requires 424.2482).

Preparation of 6,7-O,O-digeranyl-N-methylpapaveroline (13). To a stirred suspension of NaH (115

mg, 4.79 mmol) in DMF (15 mL) at rt under N₂ *N*-methylpapaveroline bromide⁹ (**12**, 1 g, 2.66 mmol) was added portionwise followed by a catalytic amount of hydroquinone. The mixture was stirred for 30 min. Geranyl bromide (240 mg, 1.11 mmol) was added dropwise and the mixture was stirred for 10 h. Geranyl bromide (295 mg, 1.36 mmol) and NaH (70 mg, 2.92 mmol) were added dropwise and the mixture was stirred for a further 5 h. The reaction mixture was treated and separated by prep. HPLC as described in preparation of **10** and **11** to give 6,7-*O,O*-digeranyl-*N*-methylpapaveroline (**13**, 31 mg; yield 4.1%) as trifluoroacetate. **13**: ¹H NMR (500 MHz, CD₃OD) δ 8.32 (1H, d, *J* = 7.0 Hz, H-3), 8.08 (1H, d, *J* = 7.0 Hz, H-4), 7.70 (1H, s, H-8), 7.60 (1H, s, H-5), 6.71 (1H, d, *J* = 8.5 Hz, H-5'), 6.49 (1H, d, *J* = 1.5 Hz, H-2'), 6.36 (1H, dd, *J* = 8.5, 1.5 Hz, H-6'), 5.58 (1H, t, *J* = 6.5 Hz, H-2''), 5.39 (1H, t, *J* = 6.5 Hz, H-2'''), 5.09 (1H, m, H-6''), 5.02 (1H, m, H-6'''), 4.90 (2H, d, *J* = 6.5 Hz, H-1'), 4.83 (2H, s, H-9), 4.80 (2H, d, *J* = 6.5 Hz, H-1'''), 4.30 (3H, s, N-Me), 2.15 (H-5'), 2.13 (4H, s, H-4'), 2.05 (2H, m, H-5'''), 1.98 (2H, m, H-4'''), 1.83 (3H, s, 3''-Me), 1.70 (3H, s, 3'''-Me), 1.61 (3H, s, 8''), 1.59 (3H, s, 8'''), 1.58 (3H, s, 7''-Me), 1.55 (3H, s, 7'''-Me); ¹³C NMR (125 MHz, CD₃OD) δ 158.86 (C-6), 156.93 (C-1), 154.18 (C-7), 147.50 (C-3'), 146.17 (C-4'), 144.48 (C-3''), 143.93 (C-3'''), 137.50 (C-4a), 136.61 (C-3), 132.81 (C-7''), 132.63 (C-7'''), 126.47 (C-1'), 125.62 (C-1a), 124.91 or 124.84 (C-6'' or C-6'''), 123.58 (C-4), 120.39 (C-6'), 119.65 (C-2'''), 119.32 (C-2''), 117.14 (C-5'), 116.13 (C-2'), 108.15 (C-8), 108.08 (C-5), 67.71 (C-1'), 67.33 (C-1'''), 46.28 (N-Me), 40.63 (C-4''), 40.46 (C-4'''), 34.96 (C-9), 27.30 or 27.29 (C-5'' or C-5'''), 25.91 (C-8''), 25.87 (C-8'''), 17.82 or 17.81 (7'' or 7'''-Me), 16.88 or 16.84 (3'' or 3'''-Me); SIMS *m/z* [M]⁺ 570; HRMS *m/z* [M]⁺ 570.3592 (C₃₇H₄₈NO₄ requires 570.3583).

Preparations of (±)-(cis) and (±)-(trans)-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalminium salts (15 and 16). To a stirred suspension of NaH (126 mg, 5.25 mmol) in DMF (15 mL) at room temperature under N₂ (±)-2,3,9,10-tetrademethyltetrahydropalminine hydrobromide⁹ (**14**, 1 g, 2.63 mmol) was added by portion followed by a catalytic amount of hydroquinone. The mixture was stirred for 30 min. Geranyl bromide (571 mg, 2.38 mmol) was added dropwise and the mixture was stirred for 2.5 h. Geranyl bromide (220 mg, 1.01 mmol) and NaH (50 mg, 2.08 mmol) were added again and the mixture was further stirred for 2.5 h. After decomposition of excess NaH with MeOH (1 mL), the mixture was poured onto ice-water and extracted with Et₂O followed by CHCl₃. The Et₂O and CHCl₃ phases were separately dried and evaporated. The CHCl₃ extract was subjected to preparative HPLC [0.1M NH₄OAc (0.05% TFA)/MeOH (0.05% TFA) (A/B) initial 60/40, 0/100 (30 min)] to give (±)-(cis)-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalminium salt (**15**, 29.5 mg, yield 2.0%) and (±)-(trans)-*N*-geranyl-2,3,9,10-tetrademethyltetrahydropalminium salt (**16**, 137.6 mg, yield 9.5%) as trifluoroacetates. **15**: ¹H NMR (500 MHz, CD₃OD) δ 6.78 (1H, d, *J* = 8.0 Hz, H-11), 6.72 (1H, s, H-4), 6.66 (1H, s, H-1), 6.57

(1H, d, $J = 8.0$ Hz, H-12), 5.44 (1H, t, $J = 8.0$ Hz, H-2'), 5.08 (1H, brs, H-6'), 4.58 (3H, brs, H-8, H-13a), 4.08 (2H, m, H-1'), 3.81 (1H, m, H-6), 3.54 (1H, m, H-6), 3.28 (1H, m, H-13), 3.18 (2H, m, H-5), 3.12 (1H, m, H-13), 2.22 (2H, m, H-4'), 2.20 (2H, m, H-5'), 1.65 (3H, s, 3'-Me), 1.59 (3H, s, 8'), 1.58 (3H, s, 7'-Me); ^{13}C NMR (125 MHz, CD_3OD) δ 152.82 (C-3'), 147.66 (C-3), 146.25 (C-2), 144.85 (C-10), 143.60 (C-9), 133.47 (C-7'), 124.76 (C-1a), 124.12 (C-6'), 121.90 (C-12a), 120.93 (C-4a), 119.69 (C-12), 116.59 (C-4, C-11), 114.80 (C-8a), 114.52 (C-1), 111.74 (C-2'), 64.34 (C-13a), 59.93 (C-1'), 57.06 (C-8), 51.66 (C-6), 41.04 (C-4'), 34.89 (C-13), 26.97 (C-5'), 25.78 (C-8'), 23.75 (C-5), 17.79 (7'-Me), 16.94 (3'-Me); SIMS m/z $[\text{M}]^+$ 436; HRMS m/z $[\text{M}]^+$ 436.2486 ($\text{C}_{27}\text{H}_{34}\text{NO}_4$ requires 436.2482), m/z $[\text{M}-\text{C}_{10}\text{H}_{16}]^+$ 300.1230 ($\text{C}_{17}\text{H}_{18}\text{NO}_4$ requires 300.1235); **16**: ^1H NMR (500 MHz, CD_3OD) δ 6.85 (1H, d, $J = 8.2$ Hz, H-11), 6.84 (1H, s, H-1), 6.77 (1H, d, $J = 8.2$ Hz, H-12), 6.71 (1H, s, H-4), 5.44 (1H, dd, $J = 9.5$, 5.5 Hz, H-2'), 5.14 (1H, brs, H-6'), 5.07 (1H, dd, $J = 12.5$, 5.0 Hz, H-13a), 4.72 (1H, d, $J = 15.5$ Hz, H-8), 4.17 (1H, d, $J = 15.5$ Hz, H-8), 3.89 (1H, m, H-6), 3.86 (1H, m, H-1'), 3.83 (1H, m, H-13), 3.69 (1H, m, H-6), 3.61 (1H, m, H-1'), 3.54 (1H, m, H-6), 3.26 (1H, m, H-5), 3.20 (1H, dd, $J = 12.5$, 5.0 Hz, H-13), 3.05 (1H, brs, H-5), 2.20 (4H, m, H-4', H-5'), 1.72 (3H, s, 8'), 1.66 (3H, s, 7'-Me), 1.33 (3H, s, 3'-Me); ^{13}C NMR (125 MHz, CD_3OD) δ 153.83 (C-3'), 147.37 (C-3), 146.63 (C-2), 144.95 (C-10), 143.66 (C-9), 133.45 (C-7'), 124.71 (C-6'), 122.77 (C-4a), 122.43 (C-12a), 122.06 (C-1a), 120.60 (C-12), 116.84 (C-11), 116.15 (C-4), 115.38 (C-8a), 113.45 (C-1), 111.42 (C-2'), 68.21 (C-13a), 58.43 (C-6), 57.62 (C-8), 46.96 (C-1'), 41.14 (C-4'), 29.60 (C-13), 27.10 (C-5'), 25.97 (C-8'), 24.48 (C-5), 17.79 (7'-Me), 16.0 (3'-Me); SIMS m/z $[\text{M}]^+$ 436; HRMS m/z $[\text{M}]^+$ 436.2484 ($\text{C}_{27}\text{H}_{34}\text{NO}_4$ requires 436.2482), m/z $[\text{M}-\text{C}_{10}\text{H}_{16}]^+$ 300.1230 ($\text{C}_{17}\text{H}_{18}\text{NO}_4$ requires 300.1235).

Preparation of ($\pm$)-(trans)-N-geranyl-2,3,10,11-tetrademethylpseudotetrahydropalmatinium salts (18**).** To a stirred suspension of NaH (130 mg, 5.42 mmol) in DMF (15 mL) at room temperature under N_2 ($\pm$)-2, 3, 10, 11-tetrademethylpseudotetrahydropalmatine hydrobromide⁹ (**17**, 1 g, 2.63 mmol) was added by portions followed by a catalytic amount of hydroquinone. The mixture was stirred for 30 min. Geranyl bromide (580 mg, 2.67 mmol) was added dropwise and the mixture was stirred for 4.5 h. After decomposition of excess NaH with MeOH (1 mL), the mixture was poured onto ice-water. The precipitated crystals (703 mg) were subjected to prep. HPLC [0.1M NH_4OAc (0.05% TFA)/MeOH (0.05% TFA) (A/B) initial 60/40, 0/100 (30 min)] to give ($\pm$)-(trans)-N-geranyl-2,3,10,11-tetrademethylpseudotetrahydropalmatinium trifluoroacetate (**18**; 318.8 mg; yield 21.9%). **18**: ^1H NMR (500 MHz, CD_3OD) δ 6.83 (1H, s, H-1), 6.81 (1H, s, H-12), 6.70 (1H, s, H-4), 6.55 (1H, s, H-9), 5.44 (1H, m, H-2'), 5.12 (1H, brs, H-6'), 5.07 (1H, m, H-13a), 4.39 (1H, d, $J = 15.0$ Hz, H-8), 4.34 (1H, d, $J = 15.0$ Hz, H-8), 3.87 (1H, m, H-1'), 3.85 (1H, m, H-6), 3.78 (1H, m, H-13), 3.64 (1H, m, H-1'), 3.63 (1H, m, H-6), 3.25 (1H, m, H-5), 3.15 (1H, d, $J = 13.0$ Hz, H-13), 3.04 (1H, m, H-5), 2.20 (4H, m, H-4', H-5'),

1.73 (3H, s, 8'), 1.67 (3H, s, 7'-Me), 1.32 (3H, s, 3'-Me); ^{13}C NMR (125 MHz, CD_3OD) δ 152.91 (C-3'), 147.62 (C-11), 147.39 (C-3), 146.69 (C-10), 146.63 (C-2), 133.27 (C-7'), 124.86 (C-6'), 122.72 (C-4a), 122.53 (C-12a), 122.05 (C-1a), 118.26 (C-8a), 116.26 (C-12), 116.15 (C-4), 114.17 (C-9), 113.46 (C-1), 111.41 (C-2'), 68.55 (C-13a), 61.61 (C-8), 58.27 (C-6), 46.69 (C-1'), 41.01 (C-4'), 29.83 (C-13), 27.04 (C-5'), 26.0 (C-8'), 24.38 (C-5), 17.91 (7'-Me), 16.79 (3'-Me); SIMS m/z $[\text{M}]^+$ 436; HRMS m/z $[\text{M}]^+$ 436.2487 ($\text{C}_{27}\text{H}_{34}\text{NO}_4$ requires 436.2482), m/z $[\text{M}-\text{C}_{10}\text{H}_{16}]^+$ 300.1241 ($\text{C}_{17}\text{H}_{18}\text{NO}_4$ requires 300.1235).

Antimicrobial assay. Antibacterial activities against *E. coli* (ATCC 25923) and *S. aureus* (ATCC 25922) were determined by means of the minimum inhibitory concentration (MIC) using the two-fold serial broth dilution test⁷ in liquid nutrient medium and 24-well microplates. MIC was defined as the lowest concentration of the test substance which did not induce visible growth in comparison with a blank experiment. The substances were dissolved in DMSO (final concentration 2.5%). Dilutions with the test medium furnished concentrations from 3.9-250 $\mu\text{g/mL}$. Benzalkonium and benzethonium chloride were used as standards. The several 24-well plates in which each well contained an appropriate growth medium with a different concentration of the respective test samples were incubated with the test organism. The 24-well plate was incubated at 37°C for 24 h for bacteria. Bacteria tested were preliminarily cultivated in 3% nutrient broth ('Nissui', Japan) at 37°C. All experiments were run in duplicate or triplicate.

In vitro cytotoxicity assay (SRB assay). Cytotoxicity was evaluated using a standard HTCL assay. The assay was carried out according to the standard SRB assay procedure described by Rubinstein *et al.*¹⁰ Samples were tested first by prescreening against KB at 40, 4, and 0.4 $\mu\text{g/mL}$ for a two-day exposure period. Active compounds that inhibited KB cell growth $\geq 40\%$ relative to control at 4 $\mu\text{g/mL}$ were re-tested in a dose-response study against an HTCL panel. Drug stock solutions were prepared in DMSO, and the final solvent concentration was 2% DMSO (v/v), a concentration without effect on cell replication. The human tumor cell line panel constituted of lung carcinoma (A-549), prostate carcinoma (DU-145), epidermoid carcinoma of the nasopharynx (KB), and KBvin (drug resistant), and human promyelocytic leukemia (HL-60). Cells were cultured at 37°C in RPMI-1640 with 100 $\mu\text{g/mL}$ kanamycin and 10% (v/v) fetal bovine serum in a humidified atmosphere containing 5% CO_2 . Initial seeding densities varied among the cell lines to ensure a final absorbance reading in control cultures in the range 1-2.5 A_{562} units. Drug exposure was for 3 days, and the ED_{50} value ($\mu\text{g/mL}$), the drug concentration that reduced the absorbance by 50%, was interpolated from dose-response data. Each test was performed in triplicate, and absorbance readings varied no more than 5%. ED_{50} values determined in independent tests varied no more than 30%.

In vitro cytotoxicity assay (MTT assay). All cell lines were propagated in RPMI-1640 medium

supplemented with 10% (v/v) FBS, 100 U/mL penicillin and 100 µg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. Cell viability was measured by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric method. Cells were seeded at densities of 5,000–10,000 cells/well in 96-well tissue culture plates. On day two, cells were treated with test compounds for another 72 h. After drug treatment, attached cells were incubated with MTT (0.5 mg/mL, 1 h) and subsequently solubilized in DMSO. The absorbancy at 550 nm was then measured using a microplate reader. The ED₅₀ (µg/mL) is the concentration of agent that reduced cell viability by 50% under the experimental conditions.

***In vitro* cytotoxicity assay (WST-8 assay).** *Cell Cultures.* Human promyelocytic leukemia HL-60 cells were purchased from Dainippon Pharmaceutical Co., Ltd., and maintained in RPMI-1640 medium (Sigma), supplemented with 10% heat-inactivated fetal bovine serum (Sigma) and 2 mM L-glutamine (Sigma) at 37 °C in a humidified atmosphere containing 5% CO₂. The doubling time of cells was approximately 24 h. *WST-8 Assay.*¹⁷ The test compounds were dissolved in DMSO at 50 mM and stored at -20°C. These stock solutions were further diluted with medium from 50 to 0.6 µM prior to use. The final concentrations of DMSO in the culture medium were less than 0.1%. 0.1% DMSO-treated cells were used as the control for all experiments. Cytotoxic effects of test compounds on HL-60 cells were detected by the WST-8 assay. HL-60 cells were plated at 5×10^3 cells/90 µL medium/well into 96-well plates. After overnight growth, cells were treated with various concentrations of test samples for 48 h. Following incubation with test compounds, cell viability was assayed with a Cell Counting Kit-8 (Dojindo Molecular Technologies). Ten microliters of WST-8 solution (5 mM) was added to each well and then incubated for 3 h. The relative viability of cells was determined by measuring the absorbance at 450 nm (reference at 650 nm) with a micro plate reader Anthos Lucy 2 (Aloka Co., Ltd.). The IC₅₀ (µg/mL) is the concentration of agent that reduced cell viability by 50% under the experimental conditions.

***In vitro* EBV-EA activation experiment.**²⁴ The inhibition of EBV-EA activation was assayed using Raji cells (virus non-producer) which were cultivated in 8% FBS RPMI 1640 medium. The indicator Raji cells (1×10^6 cells/ml) were incubated at 37 °C for 48 h in 1 ml of the medium containing *n*-butyric acid (4 mM, inducer), 32 pmol of TPA (20 ng/ml in DMSO), and 32, 16, 3.2, and 0.32 nmol of the test compound (DMSO solution). Smears were made from the cell suspension. The activated cells were stained by high-titer EBV-EA positive sera from nasopharyngeal carcinoma (NPC) patients and detected by a conventional indirect immunofluorescence technique. In each assay, at least 500 cells were counted, and the experiments were repeated three times. The average extent of EA induction was compared with that of positive control experiments with *n*-butyric acid (4 mM) plus TPA (32 pmol) in which EA

induction was ordinarily around 40%. In this screening method, the cell viability required for the judgment of inhibitory effects was more than 60%.

Determination of the scavenging effect on DPPH radicals.²⁵ Ethanol (100 μ l) was added to individual wells of a 96-well plate. The test compounds were dissolved in DMSO and diluted with EtOH to adjust to 500 μ M concentration. The final solvent concentration was 0.25% DMSO (v/v). The sample solution (100 μ l) was added to individuals by the 2-fold dilution, and EtOH solution (100 μ l) of DPPH radical (final concentration was 100 μ M) was also added. The final concentration of the test compounds was from 0.24 to 250 μ M. A control sample containing EtOH solution (100 μ l) of DPPH radical and EtOH (100 μ l) was prepared in the 96-well plate, which was incubated at 25 °C for 30 min in the dark. After incubation, the decrease in absorbance was determined by measuring the optical density change at 550 nm with a microplate luminescence reader Lucy 2 (ALOKA). The radical-scavenging activity expressed as % inhibition against DPPH radical, was calculated according to Yen and Duh (1994): % Inhibition = $[(A_B - A_A)/A_B] \times 100$, (A_A is the absorbance of the tested sample after 30 min; A_B is the absorbance of the blank sample). The data presented are the average from two or three independent experiments.

In vitro antimalaria screening. *Parasites.* In all of the studies described in this report, *P. falciparum* strain FCR-3(ATCC 30932) was used.^{26, 27} Human serum and erythrocytes were obtained from healthy donors, stored at 4°C and used within 10-14 days from donation. Parasites were cultured in 10% heat inactivated A⁺ human erythrocytes and suspended at a 5% hematocrit in RPMI 1640 medium (Gibco, NY) which contained 50 mg of gentamicin per liter, and 10% group A⁺ human serum and was buffered with 25 mM N-2-hydroxyethylpiperazine-N'-2-ethansulfonic acid (HEPES, pH 7.4) and 25 mM NaHCO₃. Cultures were maintained at 37 °C in a gas mixture of 5% O₂-5% CO₂-90% nitrogen.²⁸ *Drug testing.* Various concentrations of compounds, suspended in 10 μ l of distilled water, were added to individual wells of a 24-well plate. Erythrocytes with 0.3% parasitemia were added to each well in 990 μ l of culture medium to give a final hematocrit of 3%. The plates were incubated at 37 °C for 72 h under 5% O₂-5% CO₂-90% nitrogen. Parasite morphology in drug-treated culture after 72 hrs was measured by staining with Giemsa, and the number of parasitized red blood cells per 10,000 erythrocytes was counted and growth rates were calculated. All compounds were run in duplicate at each concentration. Drug-free control cultures were run simultaneously. All data points represent means of at least two experimental tests. The 50% inhibitory concentration (EC₅₀) was defined by comparison with drug-free controls incubated under the same conditions.^{29,30} *Mammalian cells.* A wild-type mouse FM3A cell line (subclone F-28-7) was supplied by the Health Sciences Research Resources Bank (Osaka, Japan).

FM3A cells were maintained in suspension culture at 37°C in a 5% CO₂ atmosphere in plastic bottles containing ES medium (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 2% heat-inactivated fetal bovine serum (Gibco, NY).^{31, 32} *Toxicity to mammalian cells.* The cell line grew with a doubling time of about 12 h. Before being exposed to drugs, cells were seeded at 990 µl of a density of 5×10^4 cells/ml, and various concentrations of compounds dispensed in 10 µl of distilled water were added to individual wells of a 24-well plate. The plates were incubated at 37 °C in a 5% CO₂ atmosphere for 48 hrs. Cell numbers were measured using a blood cell counter CC-108 (Toa Medical Electric Co., Japan). All data points represent means of at least two experimental tests. The 50% inhibitory concentration (IC₅₀) is defined by comparison with that of drug-free controls incubated under the same conditions. Cell growth inhibition is the index of cytotoxicity including cytostatic activity of the test compounds. *Selective toxicity.* Selective toxicity was estimated from the ratio (IC₅₀/EC₅₀) of the drug concentrations necessary to inhibit the growth rate of cells to 50% of the growth value between the malaria parasites and mouse mammary FM3A cells which served as a model host.³³

Anti-HIV assay. The T cell line H9 was maintained in continuous culture with complete medium (RPMI 1640 with 10% fetal calf serum [FCS] supplemented with L-glutamine) at 5% CO₂ and 37 °C. Aliquots of this cell line were used in experiments only when in the log-phase of growth. Test samples were first dissolved in DMSO. The following are the final drug concentrations routinely used for screening: 100, 20, 4, and 0.8 µg/mL. For active agents, additional dilutions are prepared for subsequent testing so that accurate EC₅₀ values (see definition below) could be achieved. As the test samples were being prepared, an aliquot of H9 cells was infected with HIV-1 (IIIB isolate), while another aliquot was mock-infected with complete medium. The mock-infected sample was used for toxicity determinations (IC₅₀, see definition below). The stock virus used for these studies typically had a TCID₅₀ value of 10⁴ Infectious Units (IU)/mL. The appropriate amount of virus for a multiplicity of infection between 0.1 and 0.01 IU/cell was added to the first aliquot of cells. The other aliquot of cells received only culture medium and was then incubated under identical conditions to the HIV-infected cells. After 4 h incubation at 37 °C and 5% CO₂, both cell populations were washed three times with fresh medium and then added to the appropriate wells of a 24-well plate containing various concentrations of the test drug or culture medium (positive infected control/negative-control drug). In addition, AZT was also assayed during each experiment as a positive-control drug. The plates were incubated at 37 °C and 5% CO₂ for 4 days. Cell-free supernatants were collected on day 4 and tested by an in-house p24 antigen ELISA assay; p24 antigen is a core protein of HIV and, therefore, is an indirect measure of virus present in the supernatants. Toxicity was determined by performing cell counts by a coulter counter on the mock-infected cells, which had received either culture medium (no toxicity), test sample or AZT. If a

test sample had suppressive capability and was not toxic, its effects were reported in the following terms: IC₅₀, the concentration of test sample that was toxic to 50% of the mock-infected cells; EC₅₀, the concentration of the test sample that was able to suppress HIV replication by 50%; and therapeutic index (TI), the ratio of IC₅₀ to EC₅₀.

ACKNOWLEDGEMENT

This work was supported in part by a grant from the National Cancer Institute Grant CA-17625 awarded to K. H. Lee.

REFERENCES.

1. F. Pojer, E. Wemakor, B. Kammerer, H. Chen, C. T. Walsh, S.-M. Li, and L. Heide, *Proc. Natl. Acad. Sci.*, 2003, USA 100, 2316.
2. D. J. Edwards and W. H. Gerwick, *J. Am. Chem. Soc.*, 2004, **126**, 11432.
3. T. Kuzuyama, J. P. Noel, and S. B. Richard, *Nature*, 2005, **435**, 983.
4. M. Tello, T. Kuzuyama, L. Heide, J. P. Noel, S. B. Richard, *Cell Mol. Life Sci.*, 2008, **65**, 1459.
5. S.-M. Li, *Phytochemistry*, 2009, **70**, 1746.
6. T. Usui, M. Kondoh, C. B. Cui, T. Mayumi, and H. Osada, *Biochem. J.*, 1998, **333**, 543.
7. B. Botta, A. Vitali, P. Menendez, D. Misiti, and M. G. Delle, *Curr. Med. Chem.*, 2005, **12**, 717.
8. K. Iwasa, M. Moriyasu, Y. Tachibana, H.-S Kim, Y. Wataya, W. Wiegrebe, K. F. Bastow, L. M. Cosentino, M. Kozuka, and K. H. Lee, *Bioorg. Med. Chem.*, 2001, **9**, 2871.
9. W. H. Cui, K. Iwasa, H. Tokuda, A. Kashiwara, Y. Mitani, T. Hasegawa, Y. Nishiyama, M. Moriyasu, H. Nishino, M. Hanaoka, C. Mukai, and K. Takeda, *Phytochemistry*, 2006, **67**, 70.
10. L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simo, R. S. Tosini, P. Skehan, P. A. Scudiero, A. Monks, and M. R. Boyd, *J. Natl. Cancer Inst.*, 1990, **82**, 1113.
11. Y. Ito, S. Yanase, J. Fujita, T. Harayama, T. Takashima, and H. Imanaka, *Cancer Lett.*, 1981, **13**, 29.
12. Y. Kashiwada, F. Hashimoto, L. M. Cosentino, C. H. Chen, P. E. Garrett, and K. H. Lee, *J. Med. Chem.*, 1996, **39**, 1016.
13. K. Iwasa, S. Okada, Y. Nishiyama, S. Takeuchi, M. Moriyasu, C. Tode, M. Sugiura, A. Takeuchi, H. Tokuda, K. Takeda, Y.-N. Liu, P.-C. Wu, K. F. Bastow, T. Akiyama, and K. H. Lee, *Heterocycles*, 2009, **77**, 1355.
14. B. Delley, *J. Chem. Phys.*, 1990, **92**, 508.
15. B. Delley, *J. Chem. Phys.*, 2000, **113**, 7756.
16. T. Mosmann, *J. Immunol. Methods*, 1983, **16**, 55.

17. M. Ishiyama, Y. Miyazono, K. Sasamoto, Y. Ohkura, and K. Ueno, *Taranta*, 1997, **44**, 1299.
18. A. Murakami, H. Ohigashi, and K. Koshimizu, [*Biosci. Biotechnol. Biochem.*, 1996, **60**, 1.](#)
19. K. Yasukawa, M. Takido, T. Matsumoto, M. Takeuchi, and S. Nakagawa, [*Oncology*, 1991, **48**, 72.](#)
20. T. Konoshima, M. Takasaki, M. Kozuka, T. Nagao, H. Okabe, N. Irino, T. Nakasumi, H. Tokuda, and H. Nishino, *Biol. Pharm. Bull.*, 1995, **18**, 284.
21. J. P. Perdew and Y. Wang, [*Phys. Rev. B*, 1992, **45**, 13244.](#)
22. A. D. Becke, [*J. Chem. Phys.*, 1988, **88**, 2547.](#)
23. C. Lee, W. Yang, and R. G. Parr, *Phys. Rev. B*, 1988, **37**, 786.
24. Y. Takemura, M. Ju-ichi, C. Ito, H. Furukawa, and H. Tokuda, [*Planta Med.*, 1995, **61**, 366.](#)
25. M. S. Blois, [*Nature*, 1958, **181**, 1199.](#)
26. W. Trager and J. B. Jensen, [*Science*, 1976, **193**, 673.](#)
27. J. B. Jensen, W. Trager, and J. Doherty, [*Exp. Parasitol*, 1979, **48**, 36.](#)
28. R. W. Winter, K. A. Cornell, L. L. Johnson, M. Ignatushchenko, D. J. Hinrivhs, and M. K. Riscoe, *Antimicrob Agents Chemother.*, 1996, **40**, 1408.
29. A. V. O. Ofulla, V. C. N. Okoye, B. Khan, J. I. Githure, C. R. Roberts, A. J. Johnson, and S. K. Martin, *Am. J. Trop. Med. Hyg.*, 1993, **49**, 335.
30. H. Asahi and T. Kanazawa, [*Parasitology*, 1994, **109**, 397.](#)
31. A. Yoshioka, S. Tanaka, O. Hiraoka, Y. Koyama, Y. Hirota, D. Ayusawa, T. Seno, C. Garrett, and Y. Wataya, *J. Biol. Chem.*, 1987, **262**, 8235.
32. Y. Wataya and O. Hiraoka, [*Biochem. Biophys. Res. Commun*, 1984, **123**, 677.](#)
33. I. S. Shin, H. Tanifuji, Y. Arata, Y. Morizawa, T. Nakayama, and Y. Wataya, [*Parasitol. Res.*, 1995, **81**, 622.](#)